---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description. Covers Product description and Place of product in therapy. 274 evidence topics quoted from 130 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Investigational status and current development phase

> “The global, sham-controlled, double-masked Phase 3 ARCHER II trial is ongoing in 659 patients with GA.”
> “We do not have any products approved for sale, and we have not generated any revenue from product sales.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Submission planned; U.S. and EU filings planned on ARCHER II results, timing not announced

> “ARCHER II is a single protocol supporting a global registration path. The Phase 3 single study will be analyzed for EU filing and will be allocated into two pre-defined sub-studies for the U.S. filing and maintains strong statistical power at the sub-study level.”
> “An independent Data Monitoring Committee (DMC) will assess the ARCHER II single study Month 15 primary endpoint in the fourth quarter of 2026. If the DMC recommends that the endpoint has been met, the DMC will evaluate the two pre-specified sub-studies, with results anticipated in the first quarter of 2027. Alternatively, the DMC may recommend continuing the trial through the Month 24 primary endpoint analysis. ARCHER II completion, including Month 24 analyses, is expected in the third quarter of 2027.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

<a id="topic-2.1.1-3"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-4"></a>

##### FDA and EMA alignment on a global registration path

> “We have established a global registration path with the FDA and EMA, which supports the potential of vonaprument to be the first treatment approved in both Europe and the U.S. for the protection of vision in patients with GA. The ARCHER II single overall study will be analyzed for EU registration and allocated into two pre-defined sub-studies that will be analyzed for U.S. registration in accordance with the FDA’s two-trial recommendation.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-2.1.1-5"></a>

##### FDA alignment on best-corrected visual acuity loss as the primary outcome measure

> “Annexon has gained alignment with the U.S. Food and Drug Administration (FDA) on a Phase 3 registration program that includes using, for the first-time, the prevention of ≥15-letter loss of best corrected visual acuity (BCVA) as the primary outcome measure, as well as conducting a comparison of ANX007 to an injection agent, consistent with requests for trials across ophthalmic indications.”
> “Notably, the FDA has not required Annexon to study the slowing of lesion growth as measured by fundus autofluorescence (FAF), an anatomical endpoint used for the approval of other GA programs.”

Source: [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic)

<a id="topic-2.1.1-6"></a>

##### FDA Fast Track designation for geographic atrophy

> “The U.S. Food and Drug Administration (FDA) granted Fast Track designation to ANX007, an investigational antibody antigen-binding-fragment (Fab), for the treatment of geographic atrophy (GA).”

Source: [Annexon Biosciences second-quarter 2022 results press release (2022)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-highlights-business-and-portfolio-progress)

> “The FDA has granted Fast Track designation for tanruprubart in GBS and for vonaprument in GA, and the EMA has granted PRIME designation for vonaprument in GA, and, in the future, we may seek Fast Track designation or PRIME designation for our product candidates.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-2.1.1-7"></a>

##### EMA Priority Medicine (PRIME) designation

> “today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to ANX007 for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).”
> “The EMA granted this designation, which provides enhanced development support for priority medicines that target an unmet need, based on the Phase 2 ARCHER trial data that showed a statistically significant, durable, and dose-dependent preservation of visual function in patients with GA, as well as preclinical data supporting the protective effect of ANX007 against photoreceptor damage.”

Source: [Annexon Biosciences PRIME press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-receives-prime-designation-ema-anx007-treatment)

<a id="topic-2.1.1-8"></a>

##### EMA Product Development Coordinator pilot

> “today announced that the European Medicines Agency (EMA) has selected vonaprument (formerly ANX007) to participate in the Product Development Coordinator (PDC) pilot.”
> “The PDC pilot was launched by the EMA in July 2025 to strengthen stewardship through development support activities. With background and expertise in the therapeutic area of the product, the PDC is charged with helping PRIME designation holders efficiently navigate through various regulatory interactions, including expedited scientific advice, marketing authorization application (MAA) submission readiness activities and ad-hoc queries throughout the development program.”

Source: [Annexon Biosciences PDC pilot press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-selected-ema-participate-product-development-coordinator)

<a id="topic-2.1.1-9"></a>

##### Month 24 dual primary endpoint and open-label extension added in August 2026

> “today announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and launch of an open-label extension (OLE) study of vonaprument for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).”
> “With a dual primary endpoint strategy, ARCHER II can achieve success in protecting against vision loss at either Month 15 or 24, which are independent efficacy timepoints.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-2.1.1-10"></a>

##### Regulatory risk stated by the sponsor for the amended design

> “There can be no assurance that the FDA and comparable regulatory authorities will accept the data from our Phase 3 program, including the amended dual primary endpoint design or the OLE study, or that such data will be determined sufficient to support approval.”
> “there is no assurance that either timepoint will show a statistically significant treatment effect, that the FDA, EMA or other regulators will agree that success at one timepoint is sufficient to support approval, or that the design amendment itself will not require additional discussion, data or time to align with regulators.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-2.1.1-11"></a>

##### ARROW head-to-head trial against pegcetacoplan: planned in 2023

> “ARROW Head-to-Head Trial: The Phase 3 ARROW trial is designed to enroll approximately 500 patients with GA to evaluate a monthly dose of ANX007 versus SYFOVRE® as an injection comparator, an FDA-approved drug shown to slow lesion growth.”
> “ARCHER II is expected to begin enrollment in mid-2024, followed by ARROW in late 2024.”

Source: [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic)

<a id="topic-2.1.1-12"></a>

##### ARROW head-to-head trial against pegcetacoplan: no longer planned as of March 2025

> “The single-study program will be analyzed as two sub-studies for the U.S. in accordance with the FDA’s two-trial recommendation. The primary endpoint of ARCHER II is prevention of ≥15-letter loss of BCVA, and an objective secondary structural measure is prevention of ellipsoid zone loss, both of which measures were met in the Phase 2 ARCHER trial. Accordingly, Annexon no longer plans to conduct a second injection-controlled head-to-head Phase 3 trial”

Source: [Annexon Biosciences fourth-quarter 2024 results press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-fourth-quarter-and-year-end-2024-financial)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Annexon Biosciences

> “We are advancing two late-stage registrational programs, tanruprubart toward our first approval in Guillain-Barré Syndrome, or GBS, and vonaprument toward pivotal data in dry age-related macular degeneration, or AMD, with geographic atrophy, or GA, as well as developing ANX1502, a novel oral small molecule for autoimmune conditions.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

> “We hold worldwide commercialization rights, including through exclusive licenses, to our product candidates.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.1-2"></a>

###### International nonproprietary name: proposed INN

> “vonaprumentum”
> “immunoglobulin Fab VH-G1(CH1-10h)_L-kappa, anti-[Homo sapiens C1q (complement C1q) globular head region], monoclonal antibody”

Source: [WHO proposed INN List 134 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl134.pdf)

<a id="topic-2.1.2.1-3"></a>

###### International nonproprietary name: recommended INN

> “immunoglobulin Fab VH-G1(CH1-10h)_L-kappa, anti-[Homo sapiens C1q (complement C1q) globular head region], monoclonal antibody”
> “produced in Chinese hamster ovary (CHO) cells, non-glycosylated”

Source: [WHO recommended INN List 96 (2026)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl96.pdf)

<a id="topic-2.1.2.1-4"></a>

###### Former development code ANX007

> “today announced complete enrollment of the Phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular degeneration (AMD) with geographic atrophy (GA)”

Source: [Annexon Biosciences ARCHER II enrollment press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-announces-completion-enrollment-pivotal-phase-3-archer)

<a id="topic-2.1.2.1-5"></a>

###### Therapeutic class: antigen-binding fragment inhibiting C1q

> “Vonaprument is a clinical-stage investigational antigen-binding fragment (Fab) designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway and a key driver of neurodegeneration.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

> “Vonaprument is an investigational neuroprotective inhibitor of C1q and the classical complement cascade delivered intravitreally for dry AMD with GA, a leading cause of blindness affecting more than eight million people worldwide.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.1-6"></a>

###### Relationship to tanruprubart

> “Same anti-C1q structure as tanruprubart”
> “Modeled on established IVT Fab antibodies”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-2.1.2.1-7"></a>

###### Brand name

No evidence found.

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Dosage form in phase 3: solution for intravitreal injection

> “Form: solution for injection; Route of Administration: IVT injection”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-2.1.2.2-2"></a>

###### Molecule and dose volume in ARCHER II: 5 mg in 25 microliters

> “Small 50 kD Fab antibody”
> “Non-pegylated, with low viscosity and high potency (<10 pM)”
> “5 mg administered in 25 microliter dose (in ongoing Phase 3 ARCHER II trial)”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-2.1.2.2-3"></a>

###### Expression system and glycosylation

> “produced in Chinese hamster ovary (CHO) cells, non-glycosylated”

Source: [WHO proposed INN List 134 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl134.pdf)

<a id="topic-2.1.2.2-4"></a>

###### Doses and injection volumes in the phase 1 glaucoma studies

> “Doses were administered at volumes of 20 μL (1 mg dose), 50 μL (2.5 mg dose), and 100 μL (5 mg dose), respectively.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.2-5"></a>

###### Concentration, commercial presentation, packaging, and storage

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### WHO INN functional classification of vonaprument

> “immunosuppressant, macular degeneration”

Source: [WHO proposed INN List 134 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl134.pdf)

<a id="topic-2.1.2.4-2"></a>

###### WHO ATC classification of the approved complement inhibitors for geographic atrophy (S01XA)

| ATC code | Name |
| --- | --- |
| “S01XA31” | “pegcetacoplan” |
| “S01XA32” | “avacincaptad pegol” |

Source: [WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=S01XA)

> “Other ophthalmologicals”

Source: [WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=S01XA)

<a id="topic-2.1.2.4-3"></a>

###### AHFS classification and ATC code for vonaprument

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication under development as stated by the sponsor

> “today announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and launch of an open-label extension (OLE) study of vonaprument for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

> “today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to ANX007 for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).”

Source: [Annexon Biosciences PRIME press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-receives-prime-designation-ema-anx007-treatment)

<a id="topic-2.1.2.5-2"></a>

###### Indication as registered for the phase 3 trial

> “A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 (Vonaprument) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy”
> “Diagnosis of dry AMD with GA as determined by the Investigator and confirmed by the independent Central Reading Center.”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-2.1.2.5-3"></a>

###### Label claim sought by the sponsor: protection of vision

> “We have established a global registration path with the FDA and EMA, which supports the potential of vonaprument to be the first treatment approved in both Europe and the U.S. for the protection of vision in patients with GA.”
> “Upon completion of Month 24, all patients will have the option to receive monthly vonaprument treatment in the open-label extension (OLE) study, designed to evaluate the longer-term profile of vonaprument for inclusion in the label.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

> “Alpha allocated between Month 15 (majority) and Month 24 for efficacy in label”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-2.1.2.5-4"></a>

###### Population targeted in ARCHER II: participants with enough vision to protect

> “Enrolled patients at risk for vision loss but with enough vision to protect”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-2.1.2.5-5"></a>

###### Other indications studied: glaucoma (phase 1, supporting development in GA)

> “Phase 1b Trial of vonaprument in Glaucoma to Support Development in GA”
> “We completed single-ascending dose (n=9) and sham-controlled multiple dose (n=17) studies of intravitreal vonaprument in patients with glaucoma to evaluate safety, tolerability, pharmacokinetics and target engagement.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Antigen-binding fragment that selectively inhibits C1q

> “Vonaprument is a clinical-stage investigational antigen-binding fragment (Fab) designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway and a key driver of neurodegeneration.”
> “Vonaprument involves a differentiated neuroprotective approach designed to protect photoreceptor cells and retinal function by blocking C1q and the entire classical pathway, while allowing for normal immune activity of the lectin and alternative complement pathways.”

Source: [Annexon Biosciences Retina Society press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-present-patient-baseline-characteristics-vonaprument)

<a id="topic-2.1.2.6.1-2"></a>

###### Nonproprietary name description: anti-C1q globular head region Fab

> “immunoglobulin Fab VH-G1(CH1-10h)_L-kappa, anti-[Homo sapiens C1q (complement C1q) globular head region], monoclonal antibody”
> “produced in Chinese hamster ovary (CHO) cells, non-glycosylated”
> “immunosuppressant, macular degeneration”

Source: [WHO proposed INN List 134 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl134.pdf)

<a id="topic-2.1.2.6.1-3"></a>

###### Binding to the substrate-binding head groups of C1q

> “ANX007 is a novel high affinity monoclonal antibody antigen-binding fragment (Fab) that was designed to specifically recognize the substrate-binding head groups of C1q to functionally inhibit the classical complement cascade.”
> “The blockade of C1q prevents recruitment and activation of all downstream components within the classical pathway, including C4, C3, and C5, that drive a local immune response and tissue destruction in the retina.”

Source: [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)

<a id="topic-2.1.2.6.1-4"></a>

###### Binding affinity and preservation of the lectin and alternative pathways

> “ANX007 is an investigational, humanized antibody antigen-binding fragment that recognizes C1q and blocks its initiation of the classical complement pathway”
> “By selectively targeting C1q, ANX007 inhibits the classical pathway while leaving the lectin and alternative complement pathways intact for normal immune function and tissue homeostasis.”
> “ANX007 exhibits binding affinity for C1q (KD = 10 pM) and is a potent inhibitor of the classical complement cascade.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.6.1-5"></a>

###### Product profile: 50 kD non-pegylated Fab with the anti-C1q structure of tanruprubart

> “Modeled on established IVT Fab antibodies”
> “Same anti-C1q structure as tanruprubart”
> “Small 50 kD Fab antibody”
> “Non-pegylated, with low viscosity and high potency (<10 pM)”
> “Full target engagement of classical pathway”
> “Lectin and alternative pathway left in place for immune and homeostatic functions”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-2.1.2.6.1-6"></a>

###### Relationship to the full-length antibody ANX005

> “ANX007: non-pegylated IVT-administered Fab – fragment of ANX005”
> “C1q directly binds to synapses on stressed neurons, triggering elimination”

Source: [Lad (2025)](https://annexonbio.com/wp-content/uploads/2025/02/Lad-MacSoc-2025-C1q-inhibition-GBS-HD-GA-.pdf)

<a id="topic-2.1.2.6.1-7"></a>

###### Rationale for local C1q inhibition in geographic atrophy

> “Finally, C1q is locally produced within the retina during disease by infiltrating immune cells, indicating that its pathogenic role may be amenable to local inhibition of C1q.”
> “As described above, we believe inhibition of C1q would block all key components of the classical cascade, including C1q, C4, and C3 involved in immune cell attack and synapse pruning, as well as C5 involved in direct membrane damage.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.6.1-8"></a>

###### Proposed differences from C3 and C5 inhibition

> “However, C3 and C5 inhibitors block the central and terminal aspects of all three complement pathways.”
> “In contrast, preventing the focused binding of C1q to its substrates would block all downstream classical cascade components and their amplification to reduce overall complement activation, while leaving the clearance and tissue repair functions of the lectin and alternative complement pathways in place.”

Source: [Yednock et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9641935/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Aqueous humor C1q target engagement: phase Ib glaucoma study

> “Correspondingly, mean (SD) and median (min, max) unbound C1q at day 1 (preinjection) was 100.1 (99.9) and 51.6 (16, 254) ng/ml in sham, 110.0 (109.5) and 65.7 (23, 293) in the ANX007 2.5 mg dose group, and 110.0 (83.1) and 86.8 (14, 222) in the ANX007 5.0 mg dose groups.”
> “Unbound C1q was reduced to undetectable levels at day 29 (< 0.6 ng/ml) in aqueous humor at both dose levels in all subjects”
> “Full engagement of C1q in the aqueous humor at day 29 in all treated subjects supports monthly or less-frequent dosing of ANX007 in future clinical studies.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.6.2-2"></a>

###### Serum C1q after intravitreal dosing: phase Ia glaucoma study

> “serum unbound C1q levels were unchanged over the period of the study”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.6.2-3"></a>

###### Company summary of phase 1 target engagement

> “The studies showed that vonaprument was well-tolerated at all doses (1 mg, 2.5 mg and 5 mg) and achieved complete suppression of C1q at 2.5 mg and 5 mg.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.6.2-4"></a>

###### Dose selection for monthly intravitreal injection

> “Significant Reduction in Free C1q through 4 Weeks after Single Vonaprument Dose”
> “Patient aqueous humor PK/PD supports 5mg at least monthly intravitreal injection”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-2.1.2.6.2-5"></a>

###### In vitro binding and complement pathway selectivity

> “The binding affinity of ANX007 to purified human C1q and to C1q captured from human and cynomolgus monkey serum were similar, with EC50 values of 136 pM (7.7 ng/mL), 147 pM (8 ng/mL), and 179 pM (9.5 ng/mL), respectively”
> “ANX007 specifically inhibited classical complement-mediated activation at 6 nM (300 ng/mL) and had no effect on the lectin or the alternative pathway”

Source: [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)

<a id="topic-2.1.2.6.2-6"></a>

###### Ocular target engagement in nonhuman primates

> “In contrast, suppression of free-C1q levels was maintained at days 44 and 59 in all tissues except the optic nerve.”
> “C1q inhibition was near complete in all samples at day 44, approximately 2 weeks after the second dose.”
> “These results demonstrate that aqueous humor C1q target engagement is reflected in C1q lowering in both vitreous and the retina.”
> “Importantly, in clinical studies where vitreous and ocular tissues cannot be sampled, these data support the relevance of aqueous humor target engagement as a surrogate for retinal target engagement.”

Source: [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)

<a id="topic-2.1.2.6.2-7"></a>

###### Preclinical pharmacology: photo-oxidative photoreceptor damage model

> “In support of this hypothesis, we found that either deletion or pharmacologic inhibition of C1q was protective in an animal model of photoreceptor neuron loss induced by photo-oxidation, as shown below.”
> “C1q inhibition was shown to be protective of photoreceptor cells and retinal function in a model of photoreceptor cell damage induced by light.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.6.2-8"></a>

###### Preclinical pharmacology: intravitreal and systemic anti-C1q in a light damage model

> “Genetic deletion or pharmacological inhibition of C1q provided protection against photoreceptor cell loss and preserved receptor cell function, even when inhibition was provided after damage had occurred”
> “Interestingly, while local (intravitreal) administration of an anti-C1q antibody was protective, systemic administration was not—presumably due to local production of C1q in the retina and to lower levels of antibody penetration into the eye with systemic dosing.”

Source: [Yednock et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9641935/)

<a id="topic-2.1.2.6.2-9"></a>

###### Preclinical pharmacology: microglia, synapses, and photoreceptors after light-induced damage

> “Upon Photoreceptor Damage in a Rodent Model, Microglia Engulf C1q-Coated Synapses”
> “C1q inhibition reduced reactive microglia, synapse loss, & photoreceptor loss, and protected function”

Source: [Stanga (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Stanga-EURetina-2025-C1q-inhibition-HD-GA_.pdf)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Aqueous humor concentrations: phase Ib glaucoma study

> “Mean (SD) and median (min, max) ANX007 levels in aqueous humor on day 29 were 911 ng/ml (846) and 631 (225, 2539) ng/ml in the ANX007 2.5 mg dose group and 5345 ng/ml (6351)”
> “Dose-dependent increase in aqueous unbound ANX007 levels 29 days after a single intravitreal dose.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.6.3-2"></a>

###### Serum concentrations: phase Ia glaucoma study

> “The method for the quantitative determination of unbound ANX007 in human serum used an electrochemiluminescence immunoassay with a quantification range of 1.25 ng/ml to 250.0 ng/ml, run at a minimum required dilution of 40-fold.”
> “Serum unbound ANX007 was not detected”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.6.3-3"></a>

###### Vitreous half-life in humans

No evidence found.

<a id="topic-2.1.2.6.3-4"></a>

###### Vitreous half-life and aqueous-to-vitreous ratio in nonhuman primates

> “The ANX007 half-life was approximately 3 days in the vitreous humor.”
> “Aqueous and vitreous levels were highly correlated, and aqueous levels of free-ANX007 were approximately four-fold lower than in the vitreous”
> “The half-life of ANX007 in the vitreous following IVT administration was approximately 3 days, which is consistent with published data for other humanized monoclonal antibody fragments administered through this route”

Source: [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)

<a id="topic-2.1.2.6.3-5"></a>

###### Single-dose toxicokinetics in nonhuman primates

| Parameter | 1 mg/eye | 5 mg/eye |
| --- | --- | --- |
| Dose volume (µL) | “50” | “100 (two 50 µL doses separated by 10 minutes)” |
| Serum Cmax (ng/mL) | “BQL” | “2.03” |
| Serum AUClast (h*ng/mL) | “BQL” | “204” |
| Serum Tmax (h) | “NA” | “48” |
| Vitreous Cmax (ng/mL) | “468,000” | “2,010,000” |
| Vitreous AUClast (h*ng/mL) | “46,500,000” | “247,000,000” |
| Vitreous Tmax (h) | “6” | “6” |

Source: [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)

<a id="topic-2.1.2.6.3-6"></a>

###### Ocular tissue distribution after repeat dosing in nonhuman primates

> “At day 59 (approximately 4 weeks post-last dose), free-ANX007 persisted in vitreous and aqueous humor but not in the optic nerve, choroid, or retina.”
> “These data indicate that binding of ANX007 to C1q persists to 59 days in all tissues but the optic nerve, and that ANX007 was able to access the back of the eye”
> “Although free-Fab was no longer detected, C1q was still bound to ANX007 and thus fully inhibited in the choroid at day 59 (approximately 4 weeks post-last dose).”

Source: [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)

<a id="topic-2.1.2.6.3-7"></a>

###### Immunogenicity: phase I glaucoma studies

> “No ADAs positivity was detected during the study at any ANX007 dose level at any of the timepoints assessed.”
> “Low levels of ADA positivity were detected in 7 patients (1 patient in the sham group, 3 patients in the ANX007 2.5 mg group, and 3 patients in the ANX007 5 mg group).”
> “These patients likely represent false positives in the ADA assay, as there was no change in titer over time and ADA positivity was detected before dosing in the ANX007 groups.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.6.3-8"></a>

###### Immunogenicity and systemic exposure in nonhuman primates

> “The generation of anti-drug antibody (ADA) was assessed in a validated assay in the repeat dose 5 mg/eye study, and 9 of the 10 treated animals were ADA positive.”
> “However, the effects of ADA on the toxicokinetics of ANX007 were not included in the toxicokinetic evaluation due to the low and transient systemic exposure of ANX007 in serum”

Source: [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Age range studied: ARCHER II

> “50 Years and older (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-2.1.2.8-2"></a>

###### Age range studied: ARCHER

> “50 Years and older (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-2.1.2.8-3"></a>

###### Age range studied: phase I glaucoma studies

> “In the phase Ia study, eligible patients were aged ≥ 18 years”
> “In the phase Ib study, eligible patients were aged ≥ 18 years”
> “The mean age overall was 70 years in phase Ia and 68 years in phase Ib.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.8-4"></a>

###### Age of enrolled participants: ARCHER and ARCHER II

| Characteristic | ARCHER (N = 270) | ARCHER II (N = 659) |
| --- | --- | --- |
| Age, mean (SD) | “80.0 (8.2)” | “78.4 (8.0)” |

Source: [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf)

<a id="topic-2.1.2.8-5"></a>

###### Pregnancy, breastfeeding, and contraception: ARCHER eligibility criterion

> “A female participant is eligible if she is not pregnant or breastfeeding and is a woman of non-childbearing potential or is using a contraceptive method that is highly effective, with a failure rate of <1% during the study intervention period and for at least 30 days after the last dose of study intervention.”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-2.1.2.8-6"></a>

###### Pediatric use, renal impairment, and hepatic impairment

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Vonaprument

<a id="topic-2.1.2.9.1-1"></a>

###### Clinical drug interaction studies

No evidence found.

<a id="topic-2.1.2.9.1-2"></a>

###### Prior intravitreal treatment excluded in ARCHER

> “History of any prior IVT treatment for any indication in the study eye.”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-2.1.2.9.1-3"></a>

###### Concomitant glucocorticoids excluded in the phase Ib glaucoma study

> “Concurrent use of glucocorticoid medications administered by any ocular or systemic route. Nasal, inhaled, and dermatologic (if not administered around the eyes) glucocorticoids are permitted.”
> “Previous treatment with another humanized monoclonal antibody, Fab or Fab'2.”

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Vonaprument on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Clinical drug interaction studies

No evidence found.

<a id="topic-2.1.2.9.2-2"></a>

###### Systemic exposure after intravitreal administration as context for interaction potential

> “Importantly, no PK or PD changes were observed in the systemic circulation.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### ARCHER II: 5.0 mg per eye monthly for 24 months

> “Participants will receive vonaprument IVT injections every month during the 24-month treatment period.”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

> “5 mg administered in 25 microliter dose (in ongoing Phase 3 ARCHER II trial)”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-2.1.2.10.1-2"></a>

###### ARCHER: 5 mg monthly or every other month for 12 months

> “Patients were randomized to receive an intravitreal dose of 5mg vonaprument monthly (n=89), 5mg vonaprument every other month (n=92) or sham monthly or every other month (pooled n=89) for a treatment period of 12 months, followed by a six-month off-treatment period.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.10.1-3"></a>

###### Open-label extension: monthly dosing for 24 months

> “Participants will receive vonaprument IVT injections every month for 24 months.”

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="topic-2.1.2.10.1-4"></a>

###### Dose selection: aqueous humor target engagement in phase 1

> “Full engagement of C1q in the aqueous humor at day 29 in all treated subjects supports monthly or less-frequent dosing of ANX007 in future clinical studies.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

> “Patient aqueous humor PK/PD supports 5mg at least monthly intravitreal injection”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-2.1.2.10.1-5"></a>

###### Proposed labeled dose, dosing interval, and dose modification

No evidence found.

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Route: intravitreal injection

> “It is formulated for intravitreal (IVT) administration, with the potential to be the first targeted vision-preserving therapy for GA.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

> “Form: solution for injection; Route of Administration: IVT injection”

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="topic-2.1.2.10.2-2"></a>

###### Injection procedure in the phase 1 glaucoma studies

> “Intravitreal injection was performed under sterile conditions. Topical proparacaine was used for anesthesia. Lid margins were cleaned with Povidone-iodine 10% and povidone-iodine 5% was applied to the conjunctival surface, including the injection site.”
> “For ANX007 injection, the needle was inserted perpendicular to the sclera, 3.5 to 4 mm posterior to the limbus, between the vertical and horizontal rectus muscles.”
> “Intraocular pressure was checked postinjection. Topical antibiotics were not used postinjection.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.10.2-3"></a>

###### Sham procedure in ARCHER II

> “Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection).”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-2.1.2.10.2-4"></a>

###### Needle gauge, delivery device, and post-injection monitoring instructions for the commercial product

No evidence found.

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Current access through clinical trials and the open-label extension

> “Upon completion of Month 24, all patients have the option to receive monthly vonaprument treatment in the OLE study. The OLE study is designed to evaluate the long-term safety and benefit of vonaprument in patients with GA.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

> “Participants with a diagnosis of dry AMD with GA who completed the Phase 3 ARCHER II study (NCT06510816) and who had not permanently ceased receiving the assigned masked treatment (IVT or Sham administration) at/before the ARCHER II Month 24 Visit.”

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="topic-2.1.2.11-2"></a>

###### Manufacturing: contract manufacturers in Europe

> “We do not own or operate, and currently have no plans to establish, any manufacturing facilities.”
> “Currently, several of our suppliers are located outside of the United States, and our product candidates, tanruprubart and vonaprument, are manufactured in Europe.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-2.1.2.11-3"></a>

###### Commercial supply and technology transfer

> “We have not yet engaged any manufacturers for the commercial supply of our product candidates. Although we intend to enter into such agreements prior to commercial launch of any of our product candidates, we may be unable to enter into any such agreement or do so on commercially reasonable terms, which could have a material adverse impact upon our business.”
> “The change was attributable to an increase of $27.1 million in contract manufacturing expenses supporting the tanruprubart global regulatory submissions, as well as the manufacturing technology transfer of vonaprument to a commercial-ready facility.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.11-4"></a>

###### Commercial organization and distribution capabilities

> “Given our stage of development, we have established a small commercial organization and have not established distribution capabilities.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

> “Jake Shumacher joined Annexon as S.V.P., Ophthalmology Franchise Head, and is leading global commercial strategy and execution for vonaprument. Jake was formerly V.P., Commercial Head for IZERVAY at Astellas.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

<a id="topic-2.1.2.11-5"></a>

###### Patent protection

> “The granted U.S. patents and pending patent applications in this family include claims directed to vonaprument. The granted U.S. patents and patents that may be issued from this family expire between 2036 and 2038, absent any additional disclaimers, extensions or adjustments of patent term;”
> “The pending patent applications in this family include claims covering a pharmaceutical formulation comprising anti-C1q antibodies, including tanruprubart, vonaprument and ANX009. Patents that may be issued from this family would expire in 2043, absent any disclaimers, extensions or adjustments of patent term;”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.11-6"></a>

###### Expanded access program, HCPCS code, distribution channel, and REMS

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### ARCHER: prior intravitreal and AMD treatments excluded, oral supplements permitted

> “History of any prior IVT treatment for any indication in the study eye.”
> “Any prior treatment for AMD in the study eye (for example, surgical, radiation, thermotherapeutic, or laser intervention), except oral supplements or minerals.”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-2.1.2.12-2"></a>

###### ARCHER: procedures affecting drug distribution

> “History of glaucoma filtration surgery, minimally-invasive glaucoma surgery involving an implant, or vitrectomy surgery, or other procedure in the study eye that could affect drug distribution and/or clearance.”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-2.1.2.12-3"></a>

###### ARCHER II: concomitant and prior therapy criteria

No evidence found.

<a id="topic-2.1.2.12-4"></a>

###### Use with pegcetacoplan or avacincaptad pegol

No evidence found.

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Vonaprument on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### MIPS Quality ID 14: AMD dilated macular examination, 2023 specification

> “Percentage of patients aged 50 years and older with a diagnosis of age-related macular degeneration (AMD) who had a dilated macular examination performed which included documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage AND the level of macular degeneration severity during one or more office visits within the 12 month performance period.”
> “Process”
> “Geographic Atrophy – The advanced form of non-neovascular AMD, will have one or more zones of well- demarcated retinal pigment epithelial and/or choriocapillaris atrophy.”

Source: [Centers for Medicare & Medicaid Services Quality ID 14 (2023)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2023_Measure_014_MIPSCQM.pdf)

<a id="topic-2.1.2.13-2"></a>

###### Removal of MIPS Quality ID 14 for the 2024 performance year

> “CMS removed measure 14 because it had been topped out for several years. CMS considers process-based measures to be topped out when they have a median performance rate of at least 95%. The agency is concerned that such measures offer little opportunity for performance improvement.”

Source: [American Academy of Ophthalmology MIPS 2024 quality changes (2023)](https://www.aao.org/eyenet/article/mips-2024-what-s-new-with-quality)

<a id="topic-2.1.2.13-3"></a>

###### IRIS Registry QCDR measure IRIS63: limited to exudative AMD

> “Percentage of patients with a diagnosis of exudative age-related macular degeneration, being treated with anti-VEGF agents, with a gain of 1 Snellen line or more”

Source: [American Academy of Ophthalmology IRIS63 measure specification](https://www.aao.org/medicare/quality-reporting-measure/iris63-exudative-age-related-macular-degeneration)

<a id="topic-2.1.2.13-4"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Approved and investigational therapies for GA named by the sponsor

> “Two treatments are currently FDA-approved for GA, both receiving approval in 2023: Apellis’s Syfovre, a C3 inhibitor as well as Astellas’s avacincaptad pegol, a C5 inhibitor. There are currently no approved therapies for GA in the EU.”
> “Regeneron’s pozelimab, a C5 inhibiting monoclonal antibody combined with cemdisiran, a C5-targeted siRNA molecule dosed subcutaneously.”
> “In Phase 2, there are currently four complement-targeting agents: Aviceda Therapeutics’s AVD-104, a nanoparticle molecule that inhibits complement cascade amplification and inflammation pathways, Janssen’s JNJ-1887, a gene therapy candidate which expresses soluble CD59, a complement protein, Novartis’s iptacopan, an oral factor B inhibitor, and Perceive Bio’s VOY-101 molecule, the detailed mechanism of action of which has not been fully disclosed.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.14-2"></a>

###### Competition from approved products stated by the sponsor

> “For example, with respect to vonaprument, there are two approved products for GA which may pose competition for vonaprument, if approved.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-2.1.2.14-3"></a>

###### Sponsor contrast with C3 and C5 inhibitors: target and functional outcome

> “C3/C5 designed to target the alternative pathway to preserve RPE cells/reduce lesion growth”
> “Protection of RPE has not resulted in preservation of vision”
> “Differentiated profile: small, non-pegylated, low viscosity, limited conversion to CNV”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “current FDA-approved treatments have not shown a meaningful functional benefit after years of treatment”

Source: [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic)

<a id="topic-2.1.2.14-4"></a>

###### Sponsor characterization of comparator photoreceptor analyses

> “Only studied non-foveal patients; No data available on central retinal domains”
> “Photoreceptor protection diminishes in central subfields, area critical for visual acuity”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-2.1.2.14-5"></a>

###### Sponsor claim of vision preservation and the phase 2 primary endpoint result on which it rests

> “Vonaprument is the only investigational therapy in GA to show significant vision preservation on assessments of best corrected visual acuity, or BCVA, and low luminance visual acuity, or LLVA, demonstrating significant protection from vision loss in both normal and low light conditions, as well as significant preservation of central retinal photoreceptors necessary for visual acuity.”
> “Monthly treatment with vonaprument demonstrated nominally statistically significant reduction in BCVA ≥15-letter loss (p=0.0021) compared to sham.”
> “While the primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance, greater impact on retinal pigment epithelium loss was observed in the second six months of treatment versus the first.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.14-6"></a>

###### Comparator dosing: pegcetacoplan

> “The recommended dose for SYFOVRE is 15 mg (0.1 mL of 150 mg/mL solution) administered by intravitreal injection to each affected eye once every 25 to 60 days.”

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

###### Comparator dosing: avacincaptad pegol

> “The recommended dosage for IZERVAY is 2 mg (0.1 mL of 20 mg/mL solution) administered by intravitreal injection to each affected eye once monthly (approximately every 28 ± 7 days).”

Source: [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

###### Independent systematic review: no peer-reviewed clinical results for C1q inhibition

> “Although these therapies have progressed to clinical stages, no peer-reviewed publications reporting their clinical results are available to date. According to registry and sponsor-reported information, C1q blockade with ANX007 has progressed furthest among these candidates, advancing to Phase 3 trials following neuroprotective signals in Phase 2.”
> “As these results are not yet supported by peer-reviewed publications, they were not included in the evidence synthesis and are reported here for context only.”

Source: [Fernández-Muro et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13708414/)

<a id="topic-2.1.2.14-9"></a>

###### Head-to-head trial data against pegcetacoplan or avacincaptad pegol

No evidence found.

Additional sources: [Rowe et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42999938/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition: advanced non-neovascular AMD with well-demarcated atrophy of the RPE and choriocapillaris

> “The phenotype of GA, the advanced form of non-neovascular AMD, will have one or more zones of well-demarcated RPE and/or choriocapillaris atrophy. Drusen and other pigmentary abnormalities may surround the atrophic areas. Severe VA loss occurs more slowly in patients with GA than in patients with neovascular AMD. Geographic atrophy involving the foveal center causes approximately 10% of all AMD-related visual loss of 20/200 or worse.”
> “One or several well-demarcated zones of photoreceptor, RPE, and choriocapillaris atrophy. Drusen are usually present surrounding these zones and there may be surrounding pigment clumping. This is an advanced form of AMD when the center of the fovea is involved.”
> “Although an estimated 80% of patients with age-related macular degeneration (AMD) have non-neovascular or atrophic AMD, the neovascular form is responsible for most of the severe vision loss associated with AMD.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.1.1-2"></a>

###### Definition: confluent atrophy of photoreceptors, RPE, and choriocapillaris associated with scotoma

> “GA, also known as ‘dry AMD’, is characterized by confluent atrophy of photoreceptors, RPE and choriocapillaris and is associated with scotoma.”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

> “In the late stages of AMD, 2 distinct manifestations emerge. One is the development of confluent areas of atrophy involving photoreceptors and retinal pigment epithelium, known as geographic atrophy.”

Source: [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)

<a id="topic-2.2.1.1-3"></a>

###### Bilateral and irreversible course of geographic atrophy

> “Geographic atrophy (GA) is an advanced, vision-threatening form of age-related macular degeneration (AMD). This degenerative disease occurs with progressive loss of areas of the retinal pigment epithelium (RPE), photoreceptors, and underlying choriocapillaris.”
> “Loss of visual function because of GA is considered irreversible and usually bilateral, with half of patients developing GA in both eyes within seven years of the initial GA diagnosis.”

Source: [Boyer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5424580/)

<a id="topic-2.2.1.1-4"></a>

###### Terminology: geographic atrophy as a subset of complete RPE and outer retinal atrophy

> “Geographic atrophy (GA) is a well-established end-stage manifestation of age-related macular degeneration (AMD).”
> “Thus, GA would be considered a subset of the more comprehensive term cRORA, with cRORA encompassing macular atrophy both with and without associated CNV.”

Source: [Sadda et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11366072/)

> “The advanced non-exudative form of AMD - as described by clinico-pathological correlations and high-resolution in-vivo imaging modalities - is typically characterized by well-defined patches lacking photoreceptors, by degeneration or complete loss of retinal pigment epithelium (RPE) as well as by loss or attenuation of the choriocapillaris layer”

Source: [Schmitz-Valckenberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5115977/)

<a id="topic-2.2.1.1-5"></a>

###### Multifactorial etiology: ageing, genetic susceptibility, and smoking

> “AMD is a multifactorial disease related to aging, genetic susceptibility, and environmental risk factors such as cigarette smoking; it develops as a consequence of disruption of the normal homeostatic mechanisms of the retina.”

Source: [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)

> “Age-related macular degeneration is a multifactorial disorder, with dysregulation in the complement, lipid, angiogenic, inflammatory, and extracellular matrix pathways implicated in its pathogenesis. More than 50 genetic susceptibility loci have been identified, of which the most important are in the CFH and ARMS2 genes. The major non-genetic risk factors are smoking and low dietary intake of antioxidants (zinc and carotenoids).”

Source: [Mitchell et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30303083/)

<a id="topic-2.2.1.1-6"></a>

###### Risk factors: age, family history, ancestry, and smoking

> “The main unmodifiable risk factors for the development of advanced AMD are increasing age, Northern European ancestry, and genetic factors. Although a number of modifiable risk factors have been investigated, cigarette smoking is the main one that has been consistently identified in numerous studies.”
> “Smoking significantly increases the risk of AMD and there appears to be a dose-response relationship, because the odds ratio increases with an increased number of pack-year exposure.”
> “Smoking cessation is associated with a reduced risk of AMD progression; the risk of developing AMD in individuals who have not smoked for more than 20 years is comparable to the risk in nonsmokers.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

> “The most important risk factors for GA are increasing age and family history.”

Source: [Bakri et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10408405/)

<a id="topic-2.2.1.1-7"></a>

###### Risk factors: smoking intensity and incident AMD in prospective cohorts

> “Cigarette smoking is the most consistently reported environmental risk factor for AMD.”
> “In a large prospective cohort study of 61 862 women over a 12-year follow-up period, 1 case of AMD developed per 1708 person-years among women who currently smoked 25 or more cigarettes per day compared with 1 case per 3740 person-years among those who had never smoked.”

Source: [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)

<a id="topic-2.2.1.1-8"></a>

###### Genetic risk: heritability and the CFH and ARMS2-HTRA1 loci

> “Estimated heritability of late-stage AMD is approximately 71%”
> “indicating that approximately 71% of the risk of AMD is genetic.”

Source: [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)

> “AMD genetics are unusual in that a small number of variants underlie a large proportion of heritability. The two loci with highest population attributable risk are CFH and ARMS2–HTRA1, and all other loci have low attributable risk, through low prevalence and/or weak association (with OR <1.2)”
> “Evidence shows that ARMS2–HTRA1 risk variants increase the risk of GA development and its accelerated enlargement. However, the C3 risk variant is specifically associated with slower GA enlargement but the CFH risk variants are not associated with altered speed of GA enlargement”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

> “Patients who are homozygous for the Y402H risk allele of CFH possess a 7.4-fold increased risk of AMD.”
> “Strong linkage disequilibrium has been shown across the ARMS2-HTRA1 region, and these two genes are also strongly associated with AMD.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.1.1-9"></a>

###### Genetic risk: complement gene variants among late AMD susceptibility loci

> “Early genome-wide and targeted sequencing studies identified a common variant in the CFH gene associated with AMD risk (CFH Y402H)”
> “More recently, a meta-analysis and validation sequencing of GWAS data by the AMD Consortium, which evaluated >17,100 advanced AMD cases and >60,000 controls for common AMD risk variants, identified 19 single nucleotide polymorphisms (SNPs), of which four are contained within complement cascade genes (CFH, CFI, C3, C2/CFB).”

Source: [Boyer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5424580/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Geographic atrophy secondary to age-related macular degeneration

<a id="topic-2.2.1.2.1-1"></a>

###### Annual incidence of geographic atrophy in U.S. White adults aged 50 years and older

> “Annual incidence (estimated from prevalence) of late AMD in American whites was 3.5 per 1000 aged ≥50 years (95% credible interval 2.5, 4.7 per 1000), equivalent to 293 000 new cases in American whites per year (95% credible interval 207 000, 400 000). Incidence rates approximately quadrupled per decade in age. Annual incidence GA rates were 1.9 per 1000 aged ≥50 years, NVAMD rates were 1.8 per 1000.”

Source: [Rudnicka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25857680/)

<a id="topic-2.2.1.2.1-2"></a>

###### Number of new geographic atrophy cases per year in U.S. White adults

> “This corresponds to approximately 293 000 new cases of late AMD each year (95% credible interval 207 000, 400 000), and 160 000 (95% credible interval 107 000, 234 000) and 148 000 (95% credible interval 103 000, 207 000) for GA and NVAMD, respectively.”

Source: [Rudnicka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25857680/)

<a id="topic-2.2.1.2.1-3"></a>

###### Annual incidence of geographic atrophy by age group in U.S. White adults

> “In those aged 65 years and older the annual incidence rate for late AMD is 7.8 per 1000 (95% credible interval 5.5, 10.6), 4.3 per 1000 for GA (95% credible interval 2.9, 6.2), and 3.9 per 1000 for NVAMD (95% credible interval 2.7, 5.5).”
> “In those aged 80 years and older the annual incidence rates per 1000 are 19.4 (95% credible interval 13.8, 26.2), 10.9 (95% credible interval 7.2, 16.1), and 9.9 (95% credible interval 6.8, 14.0), respectively.”

Source: [Rudnicka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25857680/)

<a id="topic-2.2.1.2.1-4"></a>

###### Incident geographic atrophy in a high-risk clinical trial cohort over 5 years

> “Of the remaining 6530 eyes at risk, 1099 (17.3%) eyes of 883 participants developed incident GA without prior neovascular disease during mean follow-up of 4.4 years. The Kaplan-Meier rate of incident GA was 19% of eyes at 5 years.”

Source: [Keenan et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6246813/)

<a id="topic-2.2.1.2.1-5"></a>

###### Fifteen-year incidence of pure geographic atrophy in an Australian population-based cohort

> “By excluding 41 subjects with GA at baseline, of 2503 participants at risk of GA, incident pure GA (without coexisting neovascular AMD lesions) was confirmed in 57 participants, with a 15-year incidence of 3.6%.”

Source: [Joachim et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23706948/)

<a id="topic-2.2.1.2.1-6"></a>

###### Annual incidence of late AMD in Europe (geographic atrophy and neovascular AMD combined)

> “In the meta-analysis of incidence, the pooled annual incidence of any late AMD was 1.4 per 1 000 individuals (95% CI 0.8 to 2.6).”
> “Incident late AMD is estimated to increase from 400 000 per year today to 700 000 per year in 2050.”

Source: [Li et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31712255/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Geographic atrophy secondary to age-related macular degeneration

<a id="topic-2.2.1.2.2-1"></a>

###### Annual prevalence of geographic atrophy in U.S. Medicare Advantage enrollees aged 65 years and older

> “The total number of patients in the denominator was 2,175,803 (2018); 2,445,163 (2019); 2,680,322 (2020); and 2,905,366 (2021). The annual prevalence of GA was 0.56% (2018), 0.55% (2019), 0.48% (2020), and 0.51% (2021).”
> “The prevalence of GA was highest among individuals classified as White race (annual range 0.61% to 0.71%) and among patients with GA aged 75 years and older (range 0.95% to 1.11%). The proportion of patients with GA with co-occurring wet AMD was 25.6% to 28.0%.”

Source: [Saundankar et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695844/)

<a id="topic-2.2.1.2.2-2"></a>

###### Prevalence of geographic atrophy by age, race, and foveal involvement in U.S. Medicare Advantage claims

> “The annual prevalence for GA without SFI was 0.21% to 0.25% across the assessment years”
> “The annual prevalence for GA with SFI was 0.27% to 0.31% during the same period. The annual prevalence of GA also was estimated at the level of eyes, with bilateral GA prevalence between 0.24% and 0.29% and unilateral GA between 0.23% and 0.27% from 2018 to 2021.”
> “Among the individuals classified as Black race, annual prevalence ranged from 0.09% to 0.11%. The annual prevalence of GA was calculated for 2 age categories; it was higher among individuals aged 75 years and older (0.95% to 1.11%) compared with people aged younger than 75 years (0.15% to 0.18%).”

Source: [Saundankar et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695844/)

<a id="topic-2.2.1.2.2-3"></a>

###### Prevalence of geographic atrophy in U.S. Medicare Advantage claims with a 24-month ascertainment window

> “In the sensitivity analyses, including an additional 12 months for measuring prevalence, the annual prevalence of GA increased: 0.85% (2018), 0.83% (2019), 0.77% (2020), and 0.74% (2021)”
> “The lower prevalence of GA observed in claims data relative to other studies warrants careful consideration; coding practices likely will evolve with new GA therapies on the market.”

Source: [Saundankar et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695844/)

<a id="topic-2.2.1.2.2-4"></a>

###### Estimated number of people in the United States with geographic atrophy

> “Published studies estimate approximately 1 million people in the United States have GA in at least 1 eye.”

Source: [Saundankar et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695844/)

<a id="topic-2.2.1.2.2-5"></a>

###### Late AMD in U.S. adults aged 40 years and older in 2019 (geographic atrophy and neovascular AMD combined)

> “We estimated there were 1.49 million people 40 years and older (95% UI, 0.97-2.15) living with late-stage AMD, corresponding to a crude prevalence rate of 0.94% (95% UI, 0.62-1.36).”
> “Prevalence of late-stage AMD increased with age from 0.02% (95% UI, 0.01-0.05) among those 40 to 44 years (Figure 3) to 11.39% (95% UI, 6.45-18.46) among people 85 years or older.”
> “late-stage (defined as choroidal neovascularization and/or geographic atrophy in either eye)”

Source: [Rein et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9634594/)

<a id="topic-2.2.1.2.2-6"></a>

###### Late AMD in U.S. adults aged 40 years and older in 2000 (geographic atrophy and neovascular AMD combined)

> “The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% (95% confidence interval, 1.38%-1.55%), with 1.75 million citizens having AMD. The prevalence of AMD increased dramatically with age, with more than 15% of the white women older than 80 years having neovascular AMD and/or geographic atrophy.”

Source: [Friedman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15078675/)

<a id="topic-2.2.1.2.2-7"></a>

###### Global pooled prevalence of geographic atrophy by ancestry

> “Eight (21%) of the 39 studies provided information on geographic atrophy and neovascular subtypes.”
> “Subgroup analysis showed similar overall prevalence of geographic atrophy (0·44%, 95% CrI 0·15–1·36) and neovascular age-related macular degeneration (0·46%, 0·18–1·08).”
> “Europeans had a higher prevalence of geographic atrophy (1·11%, 95% CrI 0·53–2·08) than Africans (0·14%, 0·04–0·45), Asians (0·21%, 0·04–0·87), and Hispanics (0·16%, 0·05–0·46).”

Source: [Wong et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25104651/)

<a id="topic-2.2.1.2.2-8"></a>

###### Prevalence of geographic atrophy and number affected in Nordic countries

> “Prevalence of GA was estimated to 0.4% (95% confidence intervals [CI]: 0.2%-0.8%), 1.5% (95% CI: 0.7%-2.6%), and 7.6% (95% CI: 4.6%-11.3%) for individuals aged 60-69, 70-79, and 80+ years, respectively. In Nordic countries, we estimate a total of 166 307 individuals with GA in 2023, increasing to 277 893 in 2050.”

Source: [Vangsted et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37680141/)

<a id="topic-2.2.1.2.2-9"></a>

###### Prevalence of geographic atrophy in Asian populations

> “The pooled overall prevalence of GA was 1.57 per 1000 persons (95% confidence interval [CI], 1.04-2.10), which was 3 times less than that of neovascular AMD of 5.20 per 1000 persons (95% CI, 3.97-6.43). Compared with those aged 50 to 59 years, the prevalence of GA increased from 0.34 per 1000 persons (95% CI, 0.07-0.62) to 2.90 per 1000 persons (95% CI, 1.55-4.25) in those aged ≥70 years.”

Source: [Rim et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32344073/)

<a id="topic-2.2.1.2.2-10"></a>

###### Late AMD in Europe, 2013 to 2040 (geographic atrophy and neovascular AMD combined)

> “Prevalence of early AMD increased from 3.5% (95% confidence interval [CI] 2.1%–5.0%) in those aged 55–59 years to 17.6% (95% CI 13.6%–21.5%) in those aged ≥85 years; for late AMD these figures were 0.1% (95% CI 0.04%–0.3%) and 9.8% (95% CI 6.3%–13.3%), respectively.”
> “This model also displayed that the number of people with late AMD in Europe will increase from 2.7 million in 2013 to 3.9 million by 2040 (Fig 8).”

Source: [Colijn et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5755466/)

<a id="topic-2.2.1.2.2-11"></a>

###### Late AMD in Europe among adults aged 60 years and older (geographic atrophy and neovascular AMD combined)

> “Our pooled prevalence estimate of early or intermediate AMD and any late AMD in those 60 years and older was 25.3% (95% CI 18.0% to 34.4%) and 2.4% (95% CI 1.8% to 3.3%), respectively.”

Source: [Li et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31712255/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Lesion growth: pooled rate across natural history studies

> “The pooled mean GA growth rate was 1.66 mm2/year (SD = 1.27 mm2/year, I2 = 97.0%, p < 0.001) from 23 studies (3,078 patients) reported with growth rate in mm2/year and 0.33 mm/year (SD = 0.17 mm/year, I2 = 83.0%, p < 0.001) from 12 studies (1,808 patients) reported with growth rate in mm/year. Larger mean baseline GA area in mm2 was associated with larger mean growth rate in both mm2/year and mm/year (p < 0.001).”

Source: [Wang and Ying (2021)](https://pubmed.ncbi.nlm.nih.gov/32721951/)

<a id="topic-2.2.1.3-2"></a>

###### Lesion growth: constant radial enlargement in untreated eyes

> “We included 25 studies with data from 2942 eyes. The RLM yielded the best goodness of fit and predictive performance of GA progression.”
> “The GA radius enlarged at a constant rate of 0.163 mm/year (95% confidence interval, 0.158-0.167 mm/year), which was independent of time (r = -0.108). The RLM predicted the mean age of onset of GA as 67.4±5.2 years.”

Source: [Shen et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/31047226/)

<a id="topic-2.2.1.3-3"></a>

###### Lesion growth: AREDS2 cohort

> “In the prevalence cohort, the change over time in square root of GA area was 0.29 mm/year (95% CI 0.27–0.30), i.e. 0.17 disc diameters/year, or (without square root transformation) 1.42 mm2/year (1.33–1.52), i.e. 0.61 disc areas/year.”
> “GA enlargement was significantly faster for non-central than for central GA at 0.31 mm/year (0.30–0.33) and 0.22 mm/year (0.20–0.24), respectively.”

Source: [Keenan et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6246813/)

<a id="topic-2.2.1.3-4"></a>

###### Lesion growth: AREDS cohort

> “Median initial lesion size was 4.3 mm2. Average change in digital area of GA from baseline was 2.03 mm2 (standard error of the mean, 0.24 mm2) at 1 year, 3.78 mm2 (0.24 mm2) at 2 years, 5.93 mm2 (0.34 mm2) at 3 years, and 1.78 mm2 (0.086 mm2) per year overall.”

Source: [Lindblad et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6500457/)

<a id="topic-2.2.1.3-5"></a>

###### Lesion growth: prospective single-center natural history study

> “The median overall enlargement rate was 2.1 mm2/year (mean, 2.6 mm2/year). Eyes with larger areas of atrophy at baseline tended to have larger enlargement rates, but knowledge of prior rates of enlargement was the most significant factor in predicting subsequent enlargement rates.”

Source: [Sunness et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2562326/)

<a id="topic-2.2.1.3-6"></a>

###### Lesion growth and visual acuity loss over 24 months in the Proxima A and B studies

> “At 24 months, adjusted mean (standard error) change in GA lesion area from baseline was 3.87 (0.15) mm2 in participants with bilateral GA (Proxima A), 3.55 (0.16) mm2 in the fellow eye CNV cohort (Proxima B), and 2.96 (0.25) mm2 in the fellow eye intermediate AMD cohort (Proxima B).”
> “Adjusted mean (standard error) changes in BCVA and LLVA (ETDRS letters) in the study eye from baseline to 24 months were -13.88 (1.40) and -7.64 (1.20) in Proxima A, -9.49 (1.29) and -7.57 (1.26) in Proxima B fellow eye CNV cohort, and -11.48 (3.39) and -8.37 (3.02) in Proxima B fellow eye intermediate AMD cohort, respectively.”

Source: [Holekamp et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32081489/)

<a id="topic-2.2.1.3-7"></a>

###### Foveal progression: time from noncentral to central geographic atrophy in AREDS

> “Median time to developing central GA after any GA diagnosis was 2.5 years (95% confidence interval, 2.0-3.0). Average visual acuity decreased by 3.7 letters at first documentation of central GA, and by 22 letters at year 5.”

Source: [Lindblad et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6500457/)

<a id="topic-2.2.1.3-8"></a>

###### Foveal progression: 2-year and 4-year rates in AREDS2

> “For the 628 participants (and 734 eyes) whose incident GA was non-central GA at its first appearance, mean follow-up time was 4.7 years (SD 0.8; IQR 0.7). The Kaplan-Meier plot for the progression from non-central to central GA in these eyes is shown in Figure 5, with a 32% 2-year rate and a 57% 4-year rate of progression to central GA.”

Source: [Keenan et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6246813/)

<a id="topic-2.2.1.3-9"></a>

###### Foveal progression: 5-year change in a U.S. population-based cohort

> “Of 53 eyes with multiple visits, the overall increase in atrophy was 6.4 mm2 over a 5-year period. The atrophy progressed to involve the foveal center in 47% of eyes and there was a mean decrease of 17 letters read correctly.”

Source: [Klein et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2612630/)

<a id="topic-2.2.1.3-10"></a>

###### Foveal progression and visual acuity change over 24 months in the IRIS Registry

> “In total, 69 441 patients were included: 44 120 (64%) GA:GA and 25 321 (36%) GA:nAMD.”
> “In both GA:GA and GA:nAMD cohorts, nonsubfoveal study eyes had better mean (standard deviation) VA at index (67 [19.3] and 66 [20.3] letters) than subfoveal eyes (59 [23.9] and 47 [26.9] letters), and 24-month mean VA changes were similar for nonsubfoveal (−7.6 and −6.2) and subfoveal (−7.9 and −6.5) subgroups. Progression to subfoveal GA occurred in 16.7% of nonsubfoveal study eyes in the GA:GA cohort and 12.5% in the GA:nAMD cohort. More new-onset study-eye nAMD was observed in the GA:nAMD (21.6%) versus GA:GA (8.2%) cohorts.”

Source: [Rahimy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10232896/)

<a id="topic-2.2.1.3-11"></a>

###### Foveal progression in U.S. Medicare Advantage claims

> “At index, 4,781 (50.3%) individuals had GA without SFI and 4,697 (49.4%) had GA with SFI. Among individuals with GA without SFI at index, 479 (10.2%) progressed to GA with SFI during the 12-month follow-up.”
> “Significant predictors of progression to GA with SFI were wet AMD at baseline (HR [CI] = 5.70 [4.63-6.99], P < 0.001)”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.3-12"></a>

###### Visual acuity loss: annual rate in AREDS2

> “The overall change in BCVA over time was significantly less than 0 at −2.3 letters/year (−2.6 to −2.0; p<0.0001).”

Source: [Keenan et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6246813/)

<a id="topic-2.2.1.3-13"></a>

###### Visual acuity loss over 4 years by baseline acuity and lesion proximity to the fovea

> “We included 1351 eyes from 994 participants, including 594 eyes from 464 participants with 4-year BCVA follow-up.”
> “In contrast, 483 eyes that met both criteria of baseline BCVA ≥ 40 letters and GA lesions involving or within 1 mm of the foveal center showed significant BCVA loss over 4 years (mean change = −11.33 letters [95% confidence interval = −12.80 to −9.84]), with faster GA progression associated with larger BCVA loss (P < 0.001).”

Source: [Shen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13474407/)

<a id="topic-2.2.1.3-14"></a>

###### Visual acuity loss over 2 years in the lampalizumab trials

> “Approximately 75%, 50%, and 25% of study eyes experienced a ≥5-, ≥10-, and ≥15-letter loss by 2 years, respectively.”

Source: [Anegondi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39581330/)

<a id="topic-2.2.1.3-15"></a>

###### Visual acuity loss and progression to neovascular AMD in bilateral geographic atrophy in U.K. practice

> “In the worse-seeing eye, 40.1% lost ≥10 letters in 2.4 years. Among patients with baseline and 24-month VA measurements, mean VA decline was 6.1 letters in the worse-seeing eye (n = 413) and 12.4 letters in the better-seeing eye (n = 414). The rate of progression to CNV in either eye was 7.4% per patient-year.”

Source: [Chakravarthy et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29366564/)

<a id="topic-2.2.1.3-16"></a>

###### Progression to neovascular AMD after incident geographic atrophy in AREDS2

> “In eyes with incident GA, 4-year risk of subsequent neovascular AMD was 29%.”

Source: [Keenan et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6246813/)

<a id="topic-2.2.1.3-17"></a>

###### Progression from unilateral to bilateral geographic atrophy

> “Interestingly, we found that the median time to development of bilateral GA was 7 years.”

Source: [Lindblad et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6500457/)

<a id="topic-2.2.1.3-18"></a>

###### Mortality: total area of geographic atrophy and all-cause mortality

> “During a median follow-up of 6.8 years, 48 (23.0%) participants with GA died. In adjusted models, accounting for age, sex, and health status, participants with total GA area in the highest quartile had a significantly increased risk of all-cause mortality compared to those with total GA area in the lowest quartile (hazard ratio [HR], 3.42; 95% confidence interval [CI], 1.32-8.86; P = 0.011). GA effective radius growth rate, bilateral disease, and the presence of foveal center involvement were not significantly associated with mortality.”

Source: [Ahluwalia et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33742280/)

<a id="topic-2.2.1.3-19"></a>

###### Mortality: late AMD and all-cause and cardiovascular mortality (geographic atrophy and neovascular AMD combined)

> “Late AMD was associated with elevated rates of all-cause (nine studies, hazard ratio (HR) 1.20, 95% confidence interval, CI, 1.02-1.41) and cardiovascular mortality (six studies, HR 1.46, 95% CI 1.13-1.98), but early AMD was not (all-cause mortality, 10 studies, HR 1.06, 95% CI 0.98-1.14; cardiovascular mortality, five studies, HR 1.12, 95% CI 0.96-1.31).”

Source: [McGuinness et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28139151/)

> “The risk of all-cause mortality and cardiovascular mortality associated with early AMD were 1.08 (1.00-1.18) and 1.05 (0.89-1.24), and the associations with late AMD were 1.23 (1.11-1.36) and 1.28 (1.04-1.57), respectively.”

Source: [Xin et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28665868/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Disease mechanism: stressors of the RPE, drusen, and complement-mediated inflammation

> “The pathogenesis of GA is multifactorial and is generally thought to be triggered by intrinsic and extrinsic stressors of the poorly regenerative RPE, particularly oxidative stress caused by the high metabolic demand of photoreceptors, photo-oxidation, and environmental stressors such as cigarette smoke.”
> “Components of drusen (cellular debris, lipids, lipoproteins, amyloid deposits) and lipofuscin (by-products of photoreceptor outer-segment degradation, A2E), as well as other products of oxidative stress such as advanced glycation end products, are thought to trigger inflammation via multiple pathways, such as the complement cascade and the NLRP3 inflammasome. When the regulatory components in these pathways are compromised, as is the case with several GA-linked genetic risk factors in the complement cascade, this inflammation can ultimately lead to the retinal cell death characteristic of GA.”

Source: [Boyer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5424580/)

> “The underlying pathophysiology of GA is complex and thought to involve chronic inflammation due to overactivation of the complement system that leads to the loss of photoreceptors, retinal pigment epithelium (RPE), and the underlying choriocapillaris.”

Source: [Bakri et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10408405/)

<a id="topic-2.2.1.4-2"></a>

###### Ageing changes and extracellular deposits in the outer retina

> “Aging-related changes cause increasing resistance of blood vessels and reduction of choriocapillaris density, lipid and lipoprotein deposition in the Bruch membrane, and reduction in photoreceptor density.”
> “Extracellular deposits, collectively known as drusen, comprise materials such as lipids, minerals, and proteins and are implicated in the development and progression of AMD.”

Source: [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)

<a id="topic-2.2.1.4-3"></a>

###### Complement system: three lines of evidence in geographic atrophy

> “The case for complement cascade dysfunction in AMD is supported by three key lines of evidence. Landmark genome-wide association studies (GWAS) identified AMD-associated variants in complement factor genes, particularly those such as CFH that promote alternative complement pathway termination on host cells.”
> “In addition, patients with GA exhibit alterations in complement cascade components both systemically and locally within the eye. Finally, these observations are supported by preclinical research in vitro and in mice, which have demonstrated that complement dysfunction is associated with GA-like pathology.”

Source: [Boyer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5424580/)

> “Analyses of donor eye tissue demonstrated the presence of complement proteins such as C3 and C5 in drusen of patients with AMD. In addition, post-mortem studies have shown that C5b-9 (membrane attack complex) accumulates in the choriocapillaris and BrM with increasing age and in eyes with AMD”
> “Indeed, a large number of high-risk genetic variants are found in genes encoding complement system regulatory proteins (for example, CFH, CFI, C3 and FB/C2)”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

<a id="topic-2.2.1.4-4"></a>

###### Complement regulation: CFH binding to C3b and the alternative pathway

> “The CFH gene product is involved in regulation of the complement system through binding to factor C3b.”
> “An alteration of regulation that occurs from modification at the C3b site leads to a defective regulation of the alternative complement pathway and results in an up-regulation of inflammation to host cells that are mediated by the membrane attack complex.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

> “Each of the CFH Y402H, CFH R1210C, and C3 K155Q variants are predicted to reduce the interaction between CFH and C3b, thus diminishing complement cascade inactivation and potentially increasing feedback amplification of the alternative complement pathway.”

Source: [Boyer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5424580/)

<a id="topic-2.2.1.4-5"></a>

###### Complement pathways: classical pathway initiation by C1 and convergence at C3 and C5

> “The classical complement pathway is activated when the C1 complex binds specific antigen–antibody complexes, often immunoglobulin M (IgM), IgG3, or IgG1. This induces a conformational change in the C1 complex, allowing it to cleave C4 and C2 to generate the C4bC2b complex. C4bC2b acts as the C3 convertase of the classical pathway, cleaving C3 into C3a and C3b.”
> “The oldest evolutionary signaling pathway of the three, the alternative complement pathway acts both independently of, and as an amplification loop for, the classical and lectin pathways.”
> “The classical, lectin, and alternative complement pathways converge with the cleavage of C3 into C3a and C3b and the subsequent formation of the C5 convertase complexes of C4bC2bC3b (classical, lectin pathways) or C3bC3bBb (alternative complement pathway). These C5 convertase complexes cleave C5 into C5a and C5b, initiating the final steps of the complement cascade.”

Source: [Boyer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5424580/)

<a id="topic-2.2.1.4-6"></a>

###### Classical pathway and C1q in geographic atrophy: sponsor-authored review

> “However, the involvement of the different complement pathways (classical, lectin, alternative), and thus the optimal complement inhibition target, has yet to be fully defined. There is evidence that C1q, the initiating molecule of the classical pathway, is a key driver of complement activity in AMD.”
> “Multiple lines of evidence suggest that the classical pathway may be a key initiator of complement activation in GA. First, C1q is present in all layers of the outer retina in GA along with numerous C1q-activating ligands that accumulate throughout disease initiation and progression. Second, C1q and the classical pathway are implicated by retinal pathology in GA and in animal models of GA. Third, in RPE culture models, C1q triggers C5b-9 deposition on basement membrane components and contributes to induction of the inflammasome and cell necrosis. Fourth, inhibition of C1q and downstream C4 is protective in animal models of photoreceptor cell loss. Fifth, C1q accumulates on photoreceptor cell synapses in mice with age and light-induced injury, consistent with the unique role it plays in synapse elimination and neurodegeneration in other disorders.”
> “C1q is highly expressed in infiltrating macrophages within all layers of the outer retina (OPL, POS, RPE, and choroid layers) in GA”

Source: [Yednock et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9641935/)

<a id="topic-2.2.1.4-7"></a>

###### C1q and photoreceptor synapse elimination: sponsor-authored review

> “Photoreceptor cell stress in GA caused by decline in RPE function and other factors may lead to a process of synapse elimination, neuroinflammation and neuronal loss that is common in multiple neurodegenerative disorders.”
> “In GA, with declining RPE function and neuronal stress, C1q on synapses may activate the classical pathway, and as in other neurodegenerative disorders, result in compromised synapse function and microglial cell recruitment”
> “While blocking downstream components of all three pathways has provided promise in clinical studies, targeting the classical pathway in GA would provide a more selective approach with the potential for increased efficacy and safety.”

Source: [Yednock et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9641935/)

<a id="topic-2.2.1.4-8"></a>

###### Preclinical evidence: subretinal macrophage C1q in photo-oxidative retinal degeneration

> “Wild-type (WT), C1qa knockout (C1qa−/−) and mice treated with a C1q inhibitor (ANX-M1; Annexon Biosciences), were exposed to photo-oxidative damage (PD) and were observed for progressive lesion development.”
> “Retinal neutralisation of C1q, using an intravitreally-delivered anti-C1q antibody, reduced the progression of retinal degeneration following PD, while systemic delivery had no effect. Finally, retinal C1q was found to be expressed by subretinal microglia/macrophages located in the outer retina of early AMD donor eyes, and in mouse PD retinas.”
> “Our data implicate subretinal macrophages, C1q and the classical pathway in progressive retinal degeneration.”

Source: [Jiao et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6102844/)

<a id="topic-2.2.1.4-9"></a>

###### RPE dysfunction preceding photoreceptor cell death

> “Ultimately, the interplay of the above-described pathological changes including chronic tissue hypoxia owing to choriocapillaris microvasculopathy, chronic inflammation and ROS-mediated oxidative stress may lead to the actual ‘end-stage’ of AMD, which is neurodegeneration, specifically photoreceptor cell death causing irreversible vision loss. In ageing and AMD, rods degenerate ahead of cones”
> “Photoreceptor cell death is presumably directly induced by the breakdown of multiple systems that are crucial for photoreceptor outer segment morphogenesis, phototransduction and metabolic homeostasis. These systems are mainly maintained by the RPE, which, in the course of AMD undergoes degeneration, finally leading to cell death.”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

<a id="topic-2.2.1.4-10"></a>

###### Mechanisms of lesion enlargement distinct from disease onset

> “These findings suggest that biological mechanisms involved in GA enlargement differ at least partially from those underlying its nascence.”
> “Furthermore, in patients with established GA, targeting complement might not be efficacious as other factors and mechanisms have been hypothesized to drive GA enlargement”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Guideline initial evaluation: history elements

| Element of the initial history | Quoted text |
| --- | --- |
| Symptom: distortion | “Metamorphopsia” |
| Symptom: reduced acuity | “Decreased vision” |
| Symptom: central field loss | “Scotoma” |
| Symptom: low-luminance function | “Difficulties in dark adaptation” |
| Family history | “Family history, especially family history of AMD” |
| Social history | “Social history, especially a quantitative smoking history” |

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.1.5-2"></a>

###### Guideline imaging: fundus autofluorescence

> “Fundus autofluorescence is helpful to demonstrate areas of GA and monitor their progression. Some patterns of autofluorescence may predict faster rates of GA.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.1.5-3"></a>

###### Guideline imaging: optical coherence tomography and OCT-based atrophy classification

> “Optical coherence tomography defines the cross-sectional architecture of the retina, which is not possible with any other imaging technology.”
> “Newer-generation OCT modalities, including SD-OCT and swept-source (SS) OCT, are preferred technologies.”
> “Classification of atrophic AMD based on OCT has led to four proposed histology level categories: complete RPE and outer retinal atrophy (cRORA), incomplete RPE and outer retinal atrophy (iRORA), complete outer retinal atrophy, and incomplete outer retinal atrophy. Longitudinal studies are needed to validate the proposed OCT classifications.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.1.5-4"></a>

###### Guideline position on genetic testing

> “Routine genetic testing is not currently recommended.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.1.5-5"></a>

###### Fundus autofluorescence: decreased signal over atrophy and regulatory acceptance as a trial endpoint

> “FAF imaging provides high-contrast retinal images that are particularly valuable for the diagnosis and evaluation of GA as loss of RPE and fluorophores in atrophic areas is associated with a decreased FAF signal”
> “Of note, the FAF signal using blue light excitation is physiologically reduced in the central macula mainly due to signal absorbance by the macula pigments lutein and zeaxanthin”
> “Atrophy in these areas may therefore not be visible by blue light excitation FAF imaging. Hence, simultaneous OCT or NIR imaging is recommended, particularly in patients with suspected foveal involvement.”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

> “Fundus autofluorescence imaging is particularly useful for identifying and monitoring geographic atrophy progression, and regulatory authorities have accepted its application in clinical trials to assess the change in geographic atrophy lesion area as the primary outcome measure.”

Source: [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)

<a id="topic-2.2.1.5-6"></a>

###### Consensus OCT definition of complete RPE and outer retinal atrophy

> “OCT was proposed as the reference standard or base imaging method to diagnose and stage atrophy. Other methods, including fundus autofluorescence, near-infrared reflectance, and color imaging, provided complementary and confirmatory information.”
> “Specific OCT criteria to diagnose cRORA were proposed: (1) a region of hypertransmission of at least 250 μm in diameter, (2) a zone of attenuation or disruption of the RPE of at least 250 μm in diameter, (3) evidence of overlying photoreceptor degeneration, and (4) absence of scrolled RPE or other signs of an RPE tear.”
> “Features of photoreceptor degeneration include all of the following: loss of the interdigitation zone, ellipsoid zone, and external limiting membrane and thinning of the outer nuclear layer.”

Source: [Sadda et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11366072/)

<a id="topic-2.2.1.5-7"></a>

###### Consensus OCT definition of incomplete RPE and outer retinal atrophy

> “In the context of drusen, iRORA is defined on OCT as (1) a region of signal hypertransmission into the choroid and (2) a corresponding zone of attenuation or disruption of the RPE, and (3) evidence of overlying photoreceptor degeneration. The term iRORA should not be used when there is an RPE tear. Longitudinal studies confirmed the concept of progression from iRORA to cRORA.”

Source: [Guymer et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7218279/)

<a id="topic-2.2.1.5-8"></a>

###### Consensus update: en face OCT for measuring complete RPE and outer retinal atrophy

> “The CAM group affirmed the role of en face OCT as a critical adjunct to traditional B-scan analysis, for more precise measurement of the area of cRORA lesions and for distinguishing threshold cRORA from smaller incomplete retinal pigment epithelial and outer retinal atrophy lesions.”
> “The consensus panel’s adoption of the abnormal RPE band term as a unified category for RPE abnormalities may reduce confusion regarding the definition of RPE degeneration and has the potential to improve interreader variability.”

Source: [Sarraf et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456394/)

<a id="topic-2.2.1.5-9"></a>

###### Expert panel recommendations: OCT as the preferred method and the role of fundus autofluorescence

> “Panelists agreed that OCT was the preferred imaging method to identify GA because of both its ease of use and accessibility among optometrists and ophthalmologists.”
> “As disease progresses, OCT remains the primary imaging modality for GA identification because of the prominent, readily identifiable hypertransmission that occurs beyond atrophic lesions.”
> “Fundus autofluorescence does not confer much additional information compared to what can be obtained from OCT (B-scan and en face). Additionally, patient tolerance to FAF imaging is lower because of the high light intensity used during acquisition.”
> “On FAF, GA lesions appear as areas of decreased autofluorescence (hypoautofluorescence) due to a lack of lipofuscin as a result of RPE cell atrophy.”

Source: [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)

<a id="topic-2.2.1.5-10"></a>

###### Expert panel recommendations: screening examinations and referral

> “Among all ECPs, regardless of practice specialty, there was unanimous agreement that there is currently no standardized process by which GA is identified and diagnosed, thus revealing a significant unmet need.”
> “The primary ECP should inquire with the patient about GA symptoms, perform a comprehensive ocular examination that includes best-corrected visual acuity assessment, and conduct a retinal examination and OCT scan to identify any signs of AMD in one or both eyes.”
> “A nonurgent referral to a retina specialist is recommended for any suspected GA in one or both eyes, whereas a more urgent referral should be made for any patient with suspected neovascular AMD (nAMD)”

Source: [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)

<a id="topic-2.2.1.5-11"></a>

###### Delphi consensus on diagnostic imaging

> “Consensus was achieved in several topics related to diagnostic imaging, including the use of optical coherence tomography, and the urgent need for treatments and beneficial interventions to reduce the associated burden.”

Source: [Singh et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37847167/)

<a id="topic-2.2.1.5-12"></a>

###### Imaging modalities for detection and limits of visual acuity as a marker

> “Because best-corrected VA does not correlate well with GA lesions or progression, alternative clinical endpoints are being sought.”
> “Detection of GA can be achieved with a number of different imaging techniques, including color fundus photography, fluorescein angiography, fundus autofluorescence (FAF), near-infrared reflectance, and spectral-domain optical coherence tomography.”

Source: [Holz et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24433969/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Central vision: scotoma and progressive central visual field loss

> “Although GA can result in significant visual function deficits in reading, night vision, and dark adaptation, and produce dense, irreversible scotomas in the visual field, the initial decline in VA may be relatively minor if the fovea is spared.”

Source: [Holz et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24433969/)

> “Areas of GA enlarge over time, leading to progressive central visual field loss”
> “Central visual loss is typically related to late AMD stages associated with photoreceptor loss. When the areas of photoreceptor loss expand, patients often lose central vision, markedly decreasing the ability to read or recognize faces.”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

<a id="topic-2.2.1.6-2"></a>

###### Central vision: symptom onset and course compared with neovascular AMD

| Stage | Clinical manifestation |
| --- | --- |
| Geographic atrophy | “Symptom onset and progression rather slow: distortion, decline in vision, and/or central visual field defects” |
| Exudative neovascular AMD | “Symptoms may occur suddenly with rapid worsening: distortion, decline in vision, and/or central visual field defects” |

Source: [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)

<a id="topic-2.2.1.6-3"></a>

###### Visual acuity: preserved acuity with foveal sparing and loss with central involvement

> “The presence of GA in the central 1-mm zone of the macula correlates with reduced VA, whereas total geographic atrophy area correlates poorly to VA.”
> “Eyes with GA outside the fovea maintain relatively good VA, yet patients’ quality of life can be affected because the inner left subfield is associated with reading and the inner lower subfield is associated with distance vision activities.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.1.6-4"></a>

###### Reading: reduced maximum reading rate in eyes with good visual acuity

> “Half the eyes with GA, but none of the drusen eyes, had maximum reading rates below 100 words per minute.”
> “The eyes with GA with good VA have profound decreases in visual function, particularly in dim lighting and in reading.”

Source: [Sunness et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9331210/)

<a id="topic-2.2.1.6-5"></a>

###### Reading: difficulty with reading as the main patient complaint

> “The main complaint among patients was difficulties regarding daily tasks, especially reading and other near activities.”

Source: [Krogh Nielsen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37933609/)

> “All participants had issues with reading since the onset of GA. Many participants had reluctantly given up reading for pleasure, mainly because it took a lot longer.”
> “When it came to reading for necessity, participants had difficulties with reading menus, reading sell-by dates, prices and other information on products, and using card machines in shops.”

Source: [Carlton et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7510394/)

<a id="topic-2.2.1.6-6"></a>

###### Low-luminance vision: worse function in dim light and its predictive value

> “These endpoints are of particular interest because patients with AMD, especially those with GA, often experience worse functional difficulties in dimly lit environments than in bright conditions”

Source: [Lad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12882265/)

> “The baseline low-luminance deficit (LLD) in VA was a strong predictor of subsequent VA loss for all levels of baseline VA. Within the good baseline VA group, the relative risk (RR) of 3-line loss for the worse LLD group compared with the better LLD group was 2.88 (95% confidence interval [CI], 1.13-7.35).”

Source: [Sunness et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18486216/)

> “The worsening of VA in decreased luminance and foveal dark-adapted sensitivity showed severe abnormalities for the GA group. Contrast sensitivity was significantly reduced for the eyes with GA.”

Source: [Sunness et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9331210/)

<a id="topic-2.2.1.6-7"></a>

###### Dark adaptation: delayed recovery after exposure to bright light

> “In the early stages of AMD, patients commonly experience alterations in visual function characterized by a delay in dark adaptation; diminished sensitivity to contrasts; and, subsequently, the appearance of scotomas in their central visual field. As the area of atrophy increases to involve larger areas of the central retina, patients begin to experience a more pronounced deterioration in central visual acuity, slower reading speed, distorted vision, challenges in discerning colors, extremely slow recovery in dark adaptation following exposure to bright light, and substantial impairment of overall visual function”

Source: [Lad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12882265/)

> “Additionally, changes in dark adaptation may occur despite stability in BCVA, suggesting better sensitivity in the assessment of visual function loss in patients with GA”

Source: [Li et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976467/)

<a id="topic-2.2.1.6-8"></a>

###### Face recognition: difficulty recognizing faces with central field loss

> “Participants in both groups were affected by a range of symptoms from GA with most experiencing varying levels of disrupted peripheral and central vision; intolerance to brightness and glare; dizziness and problems with face recognition.”

Source: [Carlton et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7510394/)

> “GA is known to cause significant functional and psychosocial burden, where patients with subfoveal GA struggle with facial recognition, driving and navigation, and parafoveal GA causing significant issues with reading and complex visual scenes”

Source: [Li et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976467/)

> “Patients may have difficulty with seeing faces, reading whole words rather than the single letters used in visual acuity assessments, and performing fine motor tasks like sewing.”

Source: [Baker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13546186/)

<a id="topic-2.2.1.6-9"></a>

###### Light sensitivity and other patient-reported symptoms: concept elicitation interviews

> “In total, 25 symptoms and 36 impacts were reported by 19 patients with GA, with seven symptoms and 11 impacts identified as salient.”
> “The symptoms with the highest average disturbance rating were night blindness, general fatigue, dry eyes, and sleep disturbance.”
> “The impacts with the highest average disturbance rating were fear, difficulty driving, and difficulty reading.”
> “Of these VISSA-10 items, blurry vision, poor light adaptation, defective color vision, and sensitivity to brighter light have been reported by patients with GA in previous studies, but the saliency of these symptoms was not measured”

Source: [Morga et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10011295/)

<a id="topic-2.2.1.6-10"></a>

###### Driving: visual acuity below the driving standard at diagnosis of bilateral GA

> “At first record of GA, 7.1% had a VA in the better-seeing eye equal to or lower than the cutoff for blindness registration and 71.1% had a VA that would have rendered them ineligible to drive.”

Source: [Chakravarthy et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29366564/)

<a id="topic-2.2.1.6-11"></a>

###### Perceptual symptoms: Charles Bonnet syndrome visual hallucinations

> “The prevalence of CBS was 25 in 120 (20.8%). Thirteen (52%) of those with CBS were not previously informed of the disease.”
> “One in five with GA has CBS, which ranks GA as an eye disease with one of the highest reported prevalences of CBS.”

Source: [Eriksen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11736733/)

<a id="topic-2.2.1.6-12"></a>

###### Emotional symptoms: fear, frustration, and anxiety

> “However, a large proportion of patients also reported fear, frustration, and anxiety as salient symptoms with large impact.”

Source: [Krogh Nielsen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37933609/)

> “emotions experienced included fear and frustration, and these frequently crossed over into their relationships with others”

Source: [Carlton et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7510394/)

<a id="topic-2.2.1.6-13"></a>

###### Clinical signs: well-demarcated atrophy with visible choroidal vessels

> “GA has traditionally been defined on color fundus photographs (CFP) as a sharply delineated circular or oval area of hypopigmentation or depigmentation in which choroidal vessels are visible.”

Source: [Guymer et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7218279/)

Additional sources: [Heier et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32199866/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Legal blindness: share of U.S. legal blindness attributed to geographic atrophy

> “Geographic atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that can cause irreversible vision impairment and is responsible for approximately 20% of legal blindness in the United States.”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.7-2"></a>

###### Legal blindness: progression to blindness in U.S. Medicare Advantage claims

> “Among individuals with GA without SFI at index, 173 (3.6%) developed irreversible blindness, compared to 312 (6.6%) of those with SFI, and 51 (0.5%) individuals without GA.”
> “Both diagnosis of GA without SFI (hazard ratio [HR] [CI] = 6.77 [4.98-9.35], P < 0.001) and diagnosis of GA with SFI (HR [CI] = 12.59 [9.43-17.16], P < 0.001) were strongly associated with increased risk of developing irreversible blindness.”
> “Irreversible blindness was defined as any patient with a diagnosis code for blindness (ICD-10-CM = H54.0, H54.1, H54.4, H54.8) in the claims database.”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.7-3"></a>

###### Legal blindness and loss of driving eligibility in bilateral geographic atrophy in U.K. practice

> “Progression to blindness (visual acuity [VA] <20 letters or Snellen 3/60 in the better-seeing eye), driving ineligibility (VA ≤70 letters or Snellen 6/12 in the better-seeing eye)”
> “At first record of GA, 7.1% had a VA in the better-seeing eye equal to or lower than the cutoff for blindness registration and 71.1% had a VA that would have rendered them ineligible to drive. Over time, 16% became legally blind (median time to outcome, 6.2 years) and 66.7% became ineligible to drive (median time to outcome, 1.6 years).”

Source: [Chakravarthy et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29366564/)

<a id="topic-2.2.1.7-4"></a>

###### Loss of driving-level acuity and progression to 20/200 or worse over 24 months in the IRIS Registry

> “Among study eyes with VA of 20/40 or better at baseline, the rates of decline were similar in both cohorts, with 30.2% in the GA:GA cohort and 30.0% in the GA:nAMD cohort progressing to VA worse than 20/40 at 24 months.”
> “Among study eyes with VA worse than 20/40 and better than 20/200 at index, 29.7% of the GA:GA and 27.6% of the GA:nAMD cohorts progressed to VA 20/200 or worse at 24 months.”

Source: [Rahimy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10232896/)

<a id="topic-2.2.1.7-5"></a>

###### Visual impairment in eyes with geographic atrophy in European population-based studies

> “Before 2006, 54.2% of eyes with GA were visually impaired, and 79.8% of eyes suffering from CNV were visually impaired. From 2006 onward, the proportion of visually impaired eyes remained the same for GA (47.6%; P = 0.40), but dropped to 66.2% (P = 0.026) for CNV (Fig 7A).”

Source: [Colijn et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5755466/)

<a id="topic-2.2.1.7-6"></a>

###### Blindness and vision impairment due to AMD worldwide, 1990 to 2021 (all AMD subtypes combined)

> “Cases of moderate vision loss rose from 2·13 million (95% UI 1·64–2·76) in 1990 to 5·39 million (4·18–7·00) in 2021, severe vision loss increased from 0·39 million (0·28–0·51) to 0·79 million (0·58–1·03), and blindness rose from 1·12 million (0·84–1·47) to 1·88 million (1·41–2·46).”

Source: [GBD 2021 Global AMD Collaborators (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12208786/)

<a id="topic-2.2.1.7-7"></a>

###### Falls and fractures in U.S. claims databases

> “Risks of falls (RR 1.16–1.36) and fractures (RR 1.17–1.29) in the 4 years following the index date were higher in patients with GA compared with controls. Patients with bilateral GA and subfoveal involvement had the most pronounced increase in risk of falls (RR 1.42–1.49) and fractures (RR 1.33–1.45).”

Source: [Hu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006262/)

<a id="topic-2.2.1.7-8"></a>

###### Injurious falls in U.S. Medicare Advantage claims by geographic atrophy and blindness status

> “Although the overall rate of all-cause injurious falls per 100 person-years did not differ meaningfully between patients with GA only and those with no GA (P=0.122), patients with GA only had 1.24 (95% CI: 1.05, 1.45) times more all-cause falls with head injuries and 0.67 (95% CI: 0.51, 0.89) times fewer all-cause falls with joint dislocations per 100 person-years compared to patients with no GA (both P<0.05).”
> “Patients with GA + B had higher rates of both all-cause and ophthalmic condition-related injurious falls, with 1.69 (95% CI: 1.29, 2.23) times more all-cause injurious falls per 100 person-years and 5.94 (95% CI: 3.40, 10.36) times more ophthalmic condition-related injurious falls per 100 person-years than patients with GA only (both P<0.05).”

Source: [Sarda et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11559221/)

<a id="topic-2.2.1.7-9"></a>

###### Fall-related injuries in a matched U.S. Medicare Advantage cohort

> “No statistically significant differences were observed in the IRs for fall-related injuries and anxiety disorders between the matched cohorts (Table 2).”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.7-10"></a>

###### Depression: new-onset depression in a matched U.S. Medicare Advantage cohort

> “In this study, the prevalence of depression at baseline was observed in one-fifth or more of the study sample (ranged 19.9%-22.6%). Furthermore, the incidence of new onset depression during the follow-up period was greater in GA cohort than non-GA cohort (86.6 vs 77.3 per 1,000 person years, P = 0.004).”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.7-11"></a>

###### Institutionalization: nursing home or assisted living admissions in U.S. claims databases

> “Compared to controls, patients with GA also had an increased risk for hospitalization (RR 1.18–1.27), emergency department visits (RR 1.18–1.21), nursing home or assisted living admissions (RR 1.06–1.28), and outpatient visits (RR 1.05–1.08).”
> “In addition, the risk of ED visits was 18% to 21% (RR [95% CI] 1.18 [1.11–1.25] to 1.21 [1.18–1.23]) higher (Fig. S2 in the Supplementary Material), and the risk of nursing home or assisted living facility admissions was 6% to 28% (RR [95% CI] 1.06 [0.99–1.13] to 1.28 [1.24–1.31]) higher”

Source: [Hu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006262/)

Additional sources: [Danzig et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38719191/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Geographic atrophy secondary to age-related macular degeneration

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Vision-related quality of life compared with age-matched peers: NEI VFQ-25

> “Vision-related functioning and QoL were poorer in patients with vs without GA (n=137 vs 52), as demonstrated by significantly lower NEI-VFQ-25 composite score (mean, 53.1 vs 84.5 points, respectively; P<0.001), as well as lower subscale scores for near activities, distance activities, dependency, driving, social functioning, mental health, role difficulties, color vision, and peripheral vision.”
> “The lower QoL observed in the GA group remained after adjusting the NEI-VFQ-25 composite score for age and sex (adjusted difference between groups, −28.82; P<0.001).”
> “Within this study conducted in the United Kingdom, Germany, Ireland, and Canada, patients with physician-confirmed diagnosis of GA secondary to AMD were recruited and interviewed prospectively.”

Source: [Patel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6955611/)

<a id="topic-2.2.1.8.1-2"></a>

###### Driving, legal blindness registration, and loss of independence

> “Eighteen percent of patients with GA were either registered as legally blind according to legislation in the relevant country, or were going through the assessment process for registration (Table 3). Over half of patients with GA had a driving license (55.5%). However, half (52.0%) of these patients did not feel confident driving during the day and most (88.0%) did not feel confident driving at night.”
> “Based on the NEI-VFQ-25 questionnaire, fewer patients in the GA group were currently driving than those in the non-GA group (27.6% vs 69.2%, respectively), and among the patients who did not drive, 73.9% had given up driving in the GA group compared with only 25.0% in the non-GA group. Eyesight was reported as the most common reason for giving up driving in the GA group (80.9%).”

Source: [Patel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6955611/)

<a id="topic-2.2.1.8.1-3"></a>

###### Visual function and lesion determinants of NEI VFQ-25 scores

> “The VRQoL composite score was impaired: 69.96 (24.03).”
> “In the multivariable cross-sectional analysis, predictors of the VRQoL composite score were BCVA, GA size, and low-luminance visual acuity (LLVA) for the better eye and BCVA, foveal sparing status, and LLVA for the worse eye (cross-validated R2 = 0.32).”

Source: [Künzel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7405807/)

> “The most significant associations with VRQoL scores for distance and near activities were observed in the inner lower and inner left subfields of the BE, respectively. For patients with foveal-sparing GA, the LLVA of the BE stood out as the most influential variable across all VRQoL scales.”

Source: [Künzel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12872259/)

<a id="topic-2.2.1.8.1-4"></a>

###### Change in vision-related quality of life after development of geographic atrophy

> “Among AREDS participants with NEI VFQ-25 data available, 358 eyes (298 participants) developed any GA. None of the quality of life measures differed significantly pre- and post-CGA. Rasch-calibrated subscale score for visual function and composite scores declined more quickly after NCGA (difference in slope [post minus pre]: –0.10 logit/yr [95% confidence interval: –0.18, –0.01], P = 0.03; –0.78 points/yr [95% confidence interval: –1.47, –0.08], P = 0.03, respectively) and after any GA (–0.09 logit/yr [95% confidence interval: –0.16, –0.01], P = 0.02; –0.68 points/yr [95% confidence interval: –1.29, –0.07], P = 0.03, respectively).”

Source: [Prasad et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12803917/)

> “A clinically meaningful decrease in VRQOL was defined as a loss of 5 points, and the median time to significant loss of VRQOL was 4.2 years (95% CI, 3.0–5.7 years) in 259 patients,24 corresponding to a decline in 1.68 ± 4.65 NEI VFQ-25 units/year (107 patients).”

Source: [Sarda et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8667751/)

<a id="topic-2.2.1.8.1-5"></a>

###### Visual function decline over 48 weeks in the sham-controlled Chroma and Spectri trials

> “Functional end points included change in BCVA from baseline to week 48, low-luminance visual acuity, mesopic microperimetry (number of absolute scotomatous points, mean macular sensitivity), binocular and monocular maximum reading speed, and 2 validated patient-reported outcome measures: Functional Reading Independence Index and 25-item National Eye Institute Visual Function Questionnaire.”
> “Enlargement of GA area, approximately 2 mm2/year on average across all treatment groups in each study, was accompanied by overall deterioration in all functional end points.”
> “Patients with bilateral GA experienced a consistent decline in visual function over 48 weeks, but measures of visual function were not correlated strongly with GA lesion area.”

Source: [Heier et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32199866/)

<a id="topic-2.2.1.8.1-6"></a>

###### Functional reading independence

> “Qualitative interviews (n = 40) yielded a 10-item FRI Index, which was refined to seven items in quantitative testing (n = 100). Strong internal consistency (marginal reliability = 0.90) and reproducibility (intraclass correlation coefficient = 0.86) were shown.”
> “Convergent validity with binocular measures was strong (Spearman's correlation = 0.72 for reading speed, 0.66 for NEI-VFQ-25).”
> “The FRI Index demonstrated good reliability and validity in patients with GA. Further study in a broader GA population is warranted to confirm responsiveness.”

Source: [Kimel et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27893095/)

<a id="topic-2.2.1.8.1-7"></a>

###### Daily activities affected: ethnographic and focus group studies

> “Sivaprasad et al25 investigated the impact of GA on daily routine activities of 16 patients with GA in Germany, the United Kingdom (UK), and the US. Patients reported difficulties with reading (100%), driving (75%), and watching television, films, or theatre (68.8%). Other concepts reported included loss of independence (56.3%) and difficulty in recognizing faces (62.5%) or performing household activities (62.5%).25”

Source: [Sarda et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8667751/)

<a id="topic-2.2.1.8.1-8"></a>

###### Activities of daily living and NEI VFQ-39 scores: United States patient survey

> “Nearly 86% of patients (n = 88) stated that they did not currently drive.”
> “The mean (SD) driving subscale score of the NEI VFQ-39, 9.7 (20.4), was the lowest score compared with the other subscales, indicating a negative impact of GA on driving.”
> “Moderate to extreme difficulty reading a newspaper and small print (eg, medicine bottle, legal forms) was reported by 67% and 68% of patients, respectively.”
> “Losing their independence was the biggest concern reported by 56% of patients; 51% of patients worried about their eyesight most or all the time.”
> “Mean (SD) vision-specific mental health subscale score, related to the items described previously, was 46.4 (25.1).”

Source: [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11348935/)

<a id="topic-2.2.1.8.1-9"></a>

###### Depression and anxiety: Medicare Advantage claims

> “In this study, the prevalence of depression at baseline was observed in one-fifth or more of the study sample (ranged 19.9%-22.6%). Furthermore, the incidence of new onset depression during the follow-up period was greater in GA cohort than non-GA cohort (86.6 vs 77.3 per 1,000 person years, P = 0.004).”
> “Additionally, approximately 20% of patients with GA in the current study had evidence of an anxiety disorder during the follow-up period”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.8.1-10"></a>

###### Depression and visual performance in age-related macular degeneration

> “Results showed that 17 patients (33%) were depressed at baseline and had worse acuity (P = 0.04) and greater levels of vision-specific (P = 0.03) and general (P = 0.002) physical disability than nondepressed patients.”
> “An increase in depressive symptoms over time predicted a decline in self-reported visual function independent of changes in visual acuity or medical status (P < 0.05).33”

Source: [Sarda et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8667751/)

<a id="topic-2.2.1.8.1-11"></a>

###### Health utility: EQ-5D index in participants with geographic atrophy

| Acceptability of injections | Participants, No. | EQ-5D health index score, median (IQR) |
| --- | --- | --- |
| Unacceptable | “27” | “0.75 (0.65 to 0.88)” |
| Acceptable | “126” | “0.74 (0.60 to 0.84)” |

Source: [Dinah et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12464851/)

> “This cross-sectional study took place at 9 geographically dispersed UK National Health Service centers from April 2023 to April 2024 among 153 participants with treatment-naive GA in at least 1 eye.”

Source: [Dinah et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12464851/)

<a id="topic-2.2.1.8.1-12"></a>

###### Health utility values by visual acuity in the better-seeing eye: age-related macular degeneration overall

> “The mean utility value for the total group with age-related macular degeneration was 0.72 (95% confidence interval [CI], 0.66-0.78) using the time trade-off method and 0.81 (95% CI, 0.76-0.86) using the standard gamble method.”
> “Using the time trade-off method correlated with the visual acuity in the better-seeing eye, the results were as follow: group 1, 0.89 (95% CI, 0.82-0.96), group 2, 0.81 (95% CI, 0.73-0.89), group 3, 0.57 (95% CI, 0.47-0.67), group 4, 0.52 (95% CI, 0.38-0.66), and group 5, 0.40 (95% CI, 0.29-0.50).”

Source: [Brown et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10636413/)

<a id="topic-2.2.1.8.1-13"></a>

###### Patient-reported importance of functional benefit from treatment

> “Among the 153 participants, 81 (53%; 95% CI, 45-61) reported IVCIs were very much or extremely acceptable under the theoretical scenarios provided. The proportion finding IVCIs acceptable rose to 82% (95% CI, 76-88) when including those who rated prospective treatment as moderately acceptable.”
> “While current treatments do not result in vision outcome benefits, perceived effectiveness by patients was associated with acceptability, emphasizing the desire to quantify vision functional benefit concomitant with anatomical slowing of progression.”

Source: [Dinah et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12464851/)

Additional sources: [Borkar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39571793/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Incremental all-cause healthcare costs: United States Medicare Advantage claims

> “Patients with GA only incurred higher annual all-cause total healthcare costs compared to patients with no GA ($26,696 vs $25,524), spending an average of $1,171 (95% CI: 204, 2,138) more per year (P=0.018). The difference in all-cause total healthcare costs was primarily driven by higher annual OP visit costs ($10,706 vs $9,996; adjusted cost difference: $740; 95% CI: 194, 1,286; P=0.008).”
> “Compared to patients with GA only, patients with GA + VI incurred higher all-cause total healthcare costs ($35,654 vs $30,558), spending an average of $5,096 (95% CI: 2,811, 7,381) more per year (P<0.001).”
> “With the additional burden of blindness, patients with GA + B spent an average of $9,952 (95% CI: 6,172, 13,733) more per year in all-cause total healthcare costs compared to patients with GA only (P<0.001).”
> “Costs were inflation-adjusted to 2021 US dollars using the medical care component of the Consumer Price Index.”

Source: [Sarda et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11559221/)

<a id="topic-2.2.1.8.2-2"></a>

###### Healthcare resource utilization rate ratios: United States Medicare Advantage claims

> “The study included 18,119 patients with GA only, 2,285 with GA + VI, 1,716 with GA + B, and 72,476 patients without GA. Higher rates of all-cause hospitalizations (RR [95% CI]: 1.08 [1.03, 1.12]), outpatient visits (1.08 [1.05, 1.10]), other visits (1.14 [1.08, 1.21]), and falls with head injuries (1.24 [1.05, 1.45]) were observed in patients with GA vs without GA (P<0.05).”
> “Patients with GA + B had higher rates of all-cause and ophthalmic condition-related hospitalizations, ER visits, and other visits PPY than patients with GA only (all P<0.05), with 2.88 (95% CI: 2.14, 3.86) times more ophthalmic condition-related hospitalizations, 1.74 (95% CI: 1.14, 2.66) times more ophthalmic condition-related ER visits, and 2.41 (95% CI: 1.90, 3.05) times more ophthalmic condition-related other visits.”

Source: [Sarda et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11559221/)

> “Compared to controls, patients with GA also had an increased risk for hospitalization (RR 1.18–1.27), emergency department visits (RR 1.18–1.21), nursing home or assisted living admissions (RR 1.06–1.28), and outpatient visits (RR 1.05–1.08).”
> “The Clinformatics®, MarketScan, and PharMetrics datasets included 44,591, 9470, and 27,428 patients with GA, respectively.”

Source: [Hu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006262/)

> “There was no statistically significant difference between the 2 cohorts in the use of health care resources like inpatient stays, length of stay, ED visits, and telehealth services, except for higher number of outpatient visits in individuals with GA (mean [SD] = 18.3 [15.9] vs 16.7 [15.9]; GA vs non-GA cohort, respectively, P < 0.001)”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.8.2-3"></a>

###### Geographic atrophy-specific outpatient visits and costs by severity: United States commercial claims

> “A total of 28,773 GA cases were identified (mean age = 68.7; 58.5% female), of which 24% and 76% had unilateral and bilateral GA, respectively”
> “Patients with greater baseline severity in the bilateral group had a significantly higher number of outpatient (OP) visits per year (1.98 EI AMD; 2.57 for GAwoSF; 2.63 for GAwSF).”
> “Similarly, higher payer-related costs were seen in patients with bilateral GAwSF compared to bilateral EI AMD (mean [SD] $280 [$325]; $198 [$262]).”
> “Overall, however, the actual costs were not large, ranging from $56–$110, given that these were disease-specific, and not all-cause, costs and thus, we would be capturing outpatient visits that do not require any active therapy.”

Source: [Kim et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8236262/)

<a id="topic-2.2.1.8.2-4"></a>

###### Total cost of care by visual acuity impairment: IRIS Registry linked to claims

> “A total of 5827 patients were included in the closed-claims cohorts. By year 2, VA impairment was associated with an increase of more than 26% in total cost of care.”
> “In models through year 2, mild (20/25 to 20/40) and moderate (20/50 to 20/100) VA impairment were associated with a more than 30% increase in total cost of care; moderately severe VA impairment (20/125 to 20/200) was associated with a 26% increase in cost; and severe VA impairment (worse than 20/200) was associated with a 43% increase in cost (mild: adjusted cost ratio, 1.31 [95% CI, 0.98-1.74, P = .061); moderate: adjusted cost ratio, 1.37 [95% CI, 1.00-1.86], P = .045; moderately severe: adjusted cost ratio, 1.26 [95% CI, 0.86-1.83], P = .237; severe: adjusted cost ratio, 1.43 [95% CI, 0.88-2.34], P = .127).”

Source: [Borkar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13226300/)

<a id="topic-2.2.1.8.2-5"></a>

###### First-year all-cause costs and indirect costs: systematic literature review

> “In a US retrospective study (N = 14,421), mean total first-year cost postdiagnosis per patient with GA to the health-care system was US $11,672 (Figure 1).34”
> “Costs presented in the included studies were converted, as applicable, to US dollars (USD) in the reported cost year; all costs were then inflated to 2020 USD.”
> “Our review identified only 7 studies with heterogeneous methodologies reporting on resource utilization and costs associated with GA, and no economic models. We identified only one study, published in 2005, on indirect costs.”

Source: [Sarda et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8667751/)

<a id="topic-2.2.1.8.2-6"></a>

###### Societal cost of illness per person with geographic atrophy: United States estimate

| Cost category, United States, per person per year | Geographic atrophy, € (% of total) | Neovascular AMD, € (% of total) |
| --- | --- | --- |
| Direct medical cost | “327 (0.8)” | “9073 (18.5)” |
| Indirect medical cost | “12 744 (32.5)” | “3385 (7.0)” |
| Well-being cost | “11 948 (30.4)” | “13 702 (28.0)” |
| Productivity cost | “14 232 (36.3)” | “22 714 (46.5)” |
| Total | “39 251 (100)” | “48 874 (100)” |
| Financial costs | “27 303 (69.6)” | “35 172 (72)” |

Source: [Paudel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12316190/)

> “Estimated per-annum total costs attributable to late-stage AMD were €449.5 million ($512.5 million) in Bulgaria, €7.6 billion ($8.6 billion) in Germany, and €43.2 billion ($49.4 billion) in the US.”
> “The financial costs incurred due to nAMD amounted to €17.2 billion ($19.7 billion) and totaled €13.4 billion ($15.3 billion) for GA (Table 3).”
> “We observed higher direct medical costs for nAMD compared with GA across all countries. This finding is reasonable given the fact that several treatment options were available for nAMD but not for GA at the time of conducting this research.”
> “First, the patient survey data were based on a relatively small sample of participants in each country; therefore, the model may have over- or underestimated certain cost parameters.”

Source: [Paudel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12316190/)

<a id="topic-2.2.1.8.2-7"></a>

###### Direct and indirect ophthalmic resource use and costs: United Kingdom, Germany, Ireland, and Canada

> “In the 24 months before study inclusion, 85.4% of patients with GA had an ophthalmology-related visit, 81.5% had at least one test or procedure (averaging 8.2–9.6 tests/procedures per year), and 10% accessed home health care services.”
> “The associated mean annual costs for direct ophthalmological resource per patient amounted to €1772, comprising €188 for ophthalmology-related visits, €1071 for tests/procedures, €116 for drugs or other treatments, €319 for home health care services, €63 for vision-related equipment, and €14 for eye rehabilitation services (Table S6).”
> “The associated mean annual costs for indirect ophthalmological resource use per patient were €234, comprising €177 for GP visits, €12 for emergency department visits, €39 for inpatient admissions, and €7 for outpatient admissions (Table S6).”
> “The annualized average total cost (direct and indirect ophthalmic HCRU) was €2006 per patient with GA, with direct health care costs accounting for most of these costs.”

Source: [Patel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6955611/)

<a id="topic-2.2.1.8.2-8"></a>

###### Costs of vision loss and blindness in the United States: all causes

> “We estimated an economic burden of VL of $134.2 billion: $98.7 billion in direct costs and $35.5 billion in indirect costs. The largest burden components were NH ($41.8 billion), other medical care services ($30.9 billion), and reduced labor force participation ($16.2 billion), all of which accounted for 66% of the total. Those with VL incurred $16 838 per year in incremental burden.”
> “Informal care was the largest burden component for people 0 to 18 years of age, reduced labor force participation was the largest burden component for people 19 to 64 years of age, and NH costs were the largest burden component for people 65 years of age or older.”

Source: [Rein et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34560128/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Geographic atrophy secondary to age-related macular degeneration on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Caregiver time, transportation, and household tasks: United States caregiver survey

> “Eighty-three percent (83%) of caregivers reported having to drive patients to their eye appointments for GA and 76% reported having to drive patients to other medical appointments.”
> “Caregivers reported spending a median time of 10 (interquartile range: 5–25) hours per week on household tasks that the patients would have been able to perform independently if not for their visual impairment due to GA.”
> “Caregivers reported having provided support for a mean (SD) of 3.3 (4.7) years to the patient with GA they cared for, and 81% of caregivers reported living with the person they cared for.”

Source: [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11348935/)

<a id="topic-2.2.1.8.3-2"></a>

###### Caregiver employment and out-of-pocket spending: United States caregiver survey

> “A relatively high proportion of caregivers (41%) had a change in their employment status after becoming a caregiver, with 50% of them unable to work due to caregiving; 29% reported working fewer hours, and 12% retired early.”
> “Patients and caregivers reported using their own money to purchase products to assist the patient with GA, including items such as extra lighting (63% and 52%, respectively), eyeglasses (72% and 51%, respectively) or devices to assist with reading (64% and 50%, respectively).”
> “Patients and caregivers also reported significant financial burden, with 44% of patients and 37% of caregivers being concerned or very concerned about the effect of GA on their finances in the future.”

Source: [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11348935/)

<a id="topic-2.2.1.8.3-3"></a>

###### Caregiver burden scores and their association with patient vision-related quality of life

> “Regarding caregivers, mean (SD) ZBI total score was 24.8 (18.7) on a scale ranging from 0 to 88, in which higher score indicates more severe burden.”
> “Overall, Spearman rank-order correlation coefficients between NEI VFQ-39 subscale and composite scores and ZBI total score ranged from −0.63 to −0.21, indicating a correlation between vision-related QoL of the patient and the caregiver’s burden.”

Source: [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11348935/)

<a id="topic-2.2.1.8.3-4"></a>

###### Caregiver share of productivity costs: United States cost-of-illness estimate for late AMD

> “In GA, 88% of the total cost incurred due to the loss of productivity resulted from the impact on patients, while the remaining 12% of the cost was attributable to the impact on caregivers.”
> “However, in the US, particularly for GA, a sizeable proportion of productivity cost (12%) was attributed to caregivers’ loss of productivity.”
> “Productivity costs accounted for the loss of productivity and employment changes for patients and caregivers. Parameters included patient job loss, patient job reduction, caregiver job reduction due to caregiving responsibilities, caregiver job reduction due to providing transport to eye health care appointments, and caregiver loss of leisure time due to providing transport.”

Source: [Paudel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12316190/)

<a id="topic-2.2.1.8.3-5"></a>

###### Costs to patients and caregivers: systematic literature review

> “Patients and caregivers incur out-of-pocket costs; for US patients, these included vision aids such as magnifying systems, flashlights, or talking watches. Caregivers usually provided transportation and helped with household chores.5 A US retrospective cohort study of administrative claims data (n = 14,421) from 2015 to 2018 determined the mean cost to the patient with GA to be $2863 (adjusted to 2020 USD).”
> “In addition, very little information was identified on the humanistic effect on caregivers.”

Source: [Sarda et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8667751/)

<a id="topic-2.2.1.8.3-6"></a>

###### Travel companions and informal care

> “Most patients with GA reported regularly traveling with a partner or friend.”

Source: [Patel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6955611/)

> “It is clear that support, whether through informal or structured care, is vital to the wellbeing of people with GA. Despite this, the general public are often unaware of care work, which may result in this integral role being undervalued and under acknowledged.”

Source: [Caswell et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8319273/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Medicare national average office-based payment for retinal imaging, 2025 and 2026

| CPT code | 2025 non-facility total RVUs | 2026 non-facility total RVUs | 2025 non-facility pay | 2026 non-facility pay | Change in non-facility pay, 2025 to 2026 |
| --- | --- | --- | --- | --- | --- |
| 92134 (OCT, retina) | “0.97” | “0.98” | “$31.38” | “$32.73” | “4.32%” |
| 92137 (OCT angiography, retina) | “1.76” | “1.79” | “$56.93” | “$59.79” | “5.02%” |
| 92250 (fundus photography) | “1.1” | “1.11” | “$35.58” | “$37.07” | “4.20%” |
| 92235 (fluorescein angiography) | “4.72” | “4.86” | “$152.68” | “$162.33” | “6.32%” |

Source: [American Academy of Ophthalmology Medicare payment comparison (2026)](https://assets.aao.org/2026-07/Office%20-%202025%20vs%202026%20Medicare%20Pay%20Final%20Rule.pdf)

> “National average Medicare payment w/o geographic adjustments”
> “Centers for Medicare & Medicaid Services (Updated November 3, 2025)”

Source: [American Academy of Ophthalmology Medicare payment comparison (2026)](https://assets.aao.org/2026-07/Office%20-%202025%20vs%202026%20Medicare%20Pay%20Final%20Rule.pdf)

<a id="topic-2.2.1.8.4-2"></a>

###### Coding of multimodal imaging for geographic atrophy

> “The most common imaging for GA includes color fundus photography, fundus autofluorescence (FAF), near-infrared reflectance (NIR) imaging, optical coherence tomography (OCT) and OCT-angiography (OCT-A). Color fundus photography, FAF and NIR imaging all fall under the same CPT code of 92250 (Fundus photography with interpretation and report). This is a bilateral code, so it is used for imaging one eye or both.”
> “It is also important to note that fundus photography is mutually exclusive with code 92134 for OCT/SCODI (scanning computerized ophthalmic diagnostic imaging of the retina), meaning photography and OCT cannot be billed on the same day for GA. In addition, most insurances limit OCT to payments no more than twice per year.”
> “However, imaging like this can only be repeated and billed if it is necessary to assess disease progression or the advent of new disease, or when planning additional treatments.”

Source: [Legge (2024)](https://optometricmanagement.com/issues/2024/may/coding-and-billing-for-geographic-atrophy/)

<a id="topic-2.2.1.8.4-3"></a>

###### Diagnostic imaging at the index diagnosis: Medicare Advantage claims

| Diagnostic procedure received on index date | Participants with GA, n (%) |
| --- | --- |
| Any of the procedures below | “6,968 (73.3)” |
| OCT | “5,042 (53.0)” |
| Fundus photography | “2,039 (21.4)” |
| Fluorescein angiography | “600 (6.3)” |
| Fluorescein and indocyanine-green angiography at the same time | “97 (1.0)” |

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

> “The specialty of the GA diagnosing provider was determined using National Provider Identifiers, and diagnostic imaging procedures used for confirming GA diagnosis were identified using Current Procedural Terminology codes”
> “Among individuals with GA, initial diagnosis was primarily by an ophthalmologist (58.6%) followed by an optometrist (30.9%).”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.8.4-4"></a>

###### Diagnostic tests as the main driver of direct ophthalmic costs

> “A variety of tests were conducted at GA diagnosis; the most common ones (used in the 98 patients initially diagnosed with bilateral GA) were distance VA (86.7%), dilated eye examination (82.7%), optical coherence tomography (OCT; 81.6%), intraocular pressure (IOP; 67.3%), and fundus autofluorescence (FAF; 44.9%).”
> “Similar to the UK cohort study, direct HCRU in our study accounted for the majority of the mean annual total costs (88%; €1772), with diagnostics tests and procedures being the main driver (€1071 per patient).”

Source: [Patel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6955611/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Antioxidant Vitamin and Mineral Supplementation

<a id="topic-2.2.2.1.1-1"></a>

###### Guideline recommendation for antioxidant supplementation in intermediate and advanced AMD

> “Randomized, controlled clinical trials support the use of antioxidant supplementation for slowing the progression to later stages of AMD”
> “Treatment with antioxidants and minerals as described previously in the original AREDS and AREDS2 trials should be considered for patients who have progressed to intermediate or advanced AMD in at least one eye.”
> “For participants with extensive intermediate (i.e., medium-sized) drusen in one or both eyes, one or more large drusen in at least one eye, non-subfoveal GA in one eye, or advanced AMD (i.e., subfoveal GA or CNV) in one eye, the rate of development of advanced AMD at 5 years was reduced by 25% in the participants using the combination treatment of antioxidant vitamins with zinc and copper.”
> “The results of the AREDS2 support the recommendation for substitution of beta-carotene with lutein (10 mg) and zeaxanthin (2 mg).”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.2.1.1-2"></a>

###### AREDS formulation and progression to advanced AMD

> “Participants were randomly assigned to receive daily oral tablets containing: (1) antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; and beta carotene, 15 mg); (2) zinc, 80 mg, as zinc oxide and copper, 2 mg, as cupric oxide; (3) antioxidants plus zinc; or (4) placebo.”
> “Average follow-up of the 3640 enrolled study participants, aged 55–80 years, was 6.3 years, with 2.4% lost to follow-up. Comparison with placebo demonstrated a statistically significant odds reduction for the development of advanced AMD with antioxidants plus zinc (odds ratio [OR], 0.72; 99% confidence interval [CI], 0.52–0.98).”
> “The only statistically significant reduction in rates of at least moderate visual acuity loss occurred in persons assigned to receive antioxidants plus zinc (OR, 0.73; 99% CI, 0.54–0.99).”
> “Those with extensive intermediate size drusen, at least 1 large druse, noncentral geographic atrophy in 1 or both eyes, or advanced AMD or vision loss due to AMD in 1 eye, and without contraindications such as smoking, should consider taking a supplement of antioxidants plus zinc such as that used in this study.”

Source: [Age-Related Eye Disease Study Research Group (2001)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1462955/)

<a id="topic-2.2.2.1.1-3"></a>

###### AREDS2 formulation: lutein and zeaxanthin in place of beta carotene

> “Median follow-up was 5 years, with 1940 study eyes (1608 participants) progressing to advanced AMD.”
> “Comparison with placebo in the primary analyses demonstrated no statistically significant reduction in progression to advanced AMD (hazard ratio [HR], 0.90 [98.7% CI, 0.76-1.07]; P = .12 for lutein + zeaxanthin; 0.97 [98.7% CI, 0.82-1.16]; P = .70 for DHA + EPA; 0.89 [98.7% CI, 0.75-1.06]; P = .10 for lutein + zeaxanthin and DHA + EPA).”
> “More lung cancers were noted in the beta carotene vs no beta carotene group (23 [2.0%] vs 11 [0.9%], nominal P = .04), mostly in former smokers.”
> “However, because of potential increased incidence of lung cancer in former smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute in the AREDS formulation.”

Source: [Age-Related Eye Disease Study 2 Research Group (2013)](https://pubmed.ncbi.nlm.nih.gov/23644932/)

<a id="topic-2.2.2.1.1-4"></a>

###### Supplementation and geographic atrophy progression toward the fovea: post hoc analysis of AREDS and AREDS2

> “Post hoc analysis of the Age-Related Eye Diseases Study (AREDS) and AREDS2, multi-center randomized placebo-controlled trials of oral micronutrient supplementation, each with 2×2 factorial design.”
> “392 eyes (318 participants) with GA in AREDS; 1210 eyes (891 participants) with GA in AREDS2.”
> “In AREDS eyes with non-central GA (n=208), proximity-based progression towards the central macula was significantly slower with randomization to antioxidants versus none, at 50.7 μm/year (95% CI 38.0–63.4 μm/year) versus 72.9 μm/year (95% CI 61.3–84.5 μm/year; p=0.012), respectively.”
> “In AREDS2 eyes with non-central GA, in participants assigned to AREDS antioxidants without β-carotene (n=325 eyes), proximity-based progression was significantly slower with randomization to lutein/zeaxanthin versus none, at 80.1 μm/year (95% CI 60.9–99.3 μm/year) versus 114.4 μm/year (95% CI 96.2–132.7 μm/year; p=0.011), respectively.”
> “In AREDS eyes with any GA (n=392), area-based progression was not significantly different with randomization to antioxidants versus none (p=0.63).”
> “Oral micronutrient supplementation slowed GA progression towards the central macula, likely by augmenting the natural phenomenon of foveal sparing.”

Source: [Keenan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11663139/)

Additional sources: [Evans and Lawrenson (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10498493/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Photobiomodulation

<a id="topic-2.2.2.1.2-1"></a>

###### FDA De Novo authorization: indications for use

> “The Valeda Light Delivery System is intended to provide improved visual acuity in patients with best-corrected visual acuity of 20/32 through 20/70 and who have dry age-related macular degeneration (AMD) characterized by:”
> “The presence of at least 3 medium drusen (> 63 µm and ≤ 125 µm in diameter), or large drusen (> 125 µm in diameter), or non-central geographic atrophy, AND”
> “The absence of neovascular maculopathy or center-involving geographic atrophy.”
> “Safety and effectiveness in patient populations and/or conditions excluded from the clinical study has not been established.”

Source: [FDA De Novo DEN230083 (2024)](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN230083.pdf)

<a id="topic-2.2.2.1.2-2"></a>

###### Treatment regimen

> “Each treatment takes a total of 250 seconds and consists of four phases as described below.”
> “For each treatment series, the patient receives 3 treatments each week for a total of 9 treatments over a period of 3-5 weeks.”

Source: [FDA De Novo DEN230083 (2024)](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN230083.pdf)

> “Subjects were given multiwavelength PBM (590, 660, and 850 nm) or Sham treatment delivered in a series of nine sessions over 3 to 5 weeks every four months over 24 months.”

Source: [Boyer et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10885856/)

<a id="topic-2.2.2.1.2-3"></a>

###### LIGHTSITE III: best-corrected visual acuity in the FDA review

> “Using multiple imputation analysis with the mITT dataset (PBM: n = 91, Sham: n = 54), the study met the predetermined primary effectiveness BCVA endpoint at Month 21 with the following results.”
> “At Month 13: The mean PBM result was 2.6 letters better than the mean Sham result (p=0.0548; non-significant);”
> “At Month 21: The mean PBM result was 3.8 letters better than the mean Sham result (p=0.0036; significant).”
> “In terms of the primary effectiveness endpoint (difference between study arms in terms of mean BCVA change from baseline), the device demonstrated a statistically significant improvement which is of marginal clinical significance.”
> “The effect of treatment with the device past 2 years and the duration of treatment effect is also unknown at this time.”

Source: [FDA De Novo DEN230083 (2024)](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN230083.pdf)

<a id="topic-2.2.2.1.2-4"></a>

###### LIGHTSITE III: new-onset and existing geographic atrophy at Month 13

> “A very small number of eyes presented with noncenter involving GA at baseline (PBM, n = 6; Sham, n = 5).”
> “Using FAF analysis, a numerical trend showed an increase in GA lesion area in Sham (1.48, SE 0.94; SD 1.62) compared with PBM-treated eyes (1.16, SE 0.66; SD 1.32, P = 0.75) at Month 13 (change from baseline; Table 2; Figure 5).”
> “The occurrence of new GA was significantly higher in the Sham versus PBM group (P = 0.024, Fisher exact test, odds ratio 9.4) (Table 2; Figure 5).”

Source: [Boyer et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10885856/)

<a id="topic-2.2.2.1.2-5"></a>

###### Guideline appraisal and evidence grade

> “LIGHTSITE I and II and a Cochrane review in 2021 did not show a benefit of photobiomodulation”
> “but a follow-up study, LIGHTSITE III in 2024, showed that photobiomodulation appears to decrease the onset of new GA”
> “I-, Insufficient quality”
> “In 2024, the U.S. Food and Drug Administration (FDA) approved a device for multiwavelength photobiomodulation”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Complement C3 Inhibitors

<a id="topic-2.2.2.1.3-1"></a>

###### Pegcetacoplan: mechanism and FDA approval

> “On February 17, 2023, pegcetacoplan 15 mg (Syfovre, Apellis Pharmaceuticals) was approved by the US Food and Drug Administration (FDA) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD).”
> “Pegcetacoplan is a polyethylene-glycolylated (PEGylated) peptide that blocks complement factor C3, which has been implicated in the development of both the exudative and advanced atrophic forms of AMD.”

Source: [Witkin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10786078/)

<a id="topic-2.2.2.1.3-2"></a>

###### Pegcetacoplan: indication, dosage, and contraindications

> “SYFOVRE is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).”
> “SYFOVRE must be administered by a qualified physician.”
> “The recommended dose for SYFOVRE is 15 mg (0.1 mL of 150 mg/mL solution) administered by intravitreal injection to each affected eye once every 25 to 60 days.”
> “SYFOVRE is contraindicated in patients with active intraocular inflammation.”

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)

<a id="topic-2.2.2.1.3-3"></a>

###### Pegcetacoplan: retinal vasculitis and retinal vascular occlusion warning

> “Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE”
> “Cases may occur with the first dose of SYFOVRE and may result in severe vision loss.”
> “Discontinue treatment with SYFOVRE in patients who develop these events.”
> “Eye disorders: retinal vasculitis with or without retinal vascular occlusion.”

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)

<a id="topic-2.2.2.1.3-4"></a>

###### Pegcetacoplan: neovascular AMD, intraocular inflammation, and ischemic optic neuropathy

> “In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24.”
> “Patients receiving SYFOVRE should be monitored for signs of neovascular AMD.”
> “In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare.”
> “Optic ischemic neuropathy was reported in 1.7% of patients treated monthly, 0.2% of patients treated every other month and 0.0% of patients assigned to sham.”

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)

<a id="topic-2.2.2.1.3-5"></a>

###### OAKS and DERBY: design

> “The safety and efficacy of SYFOVRE were assessed in two multi-center, randomized, sham-controlled studies in patients with GA (atrophic nonexudative age-related macular degeneration), with or without subfoveal involvement, secondary to AMD in a total of 1258 randomized patients (SYFOVRE 839 patients, sham 419 patients).”
> “There was a reduction in the mean rate of GA lesion growth observed in both studies.”

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)

<a id="topic-2.2.2.1.3-6"></a>

###### OAKS and DERBY: GA lesion growth from baseline to month 24

| Study and group | Rate of GA lesion area growth (mm2), slope (SE) | Difference (95% CI) in slope from sham pooled | Percent difference from sham pooled |
| --- | --- | --- | --- |
| OAKS, pegcetacoplan monthly | “3.11 (0.148)” | “−0.87” “(−1.27 to −0.47)” | “−21.9%” |
| OAKS, pegcetacoplan every other month | “3.26 (0.134)” | “−0.72” “(−1.10 to −0.33)” | “−18.1%” |
| OAKS, sham pooled | “3.98 (0.143)” | “NA” | “NA” |
| DERBY, pegcetacoplan monthly | “3.28 (0.125)” | “−0.73” “(−1.14 to −0.31)” | “−18.1%” |
| DERBY, pegcetacoplan every other month | “3.31 (0.129)” | “−0.70” “(−1.11 to −0.28)” | “−17.4%” |
| DERBY, sham pooled | “4.00 (0.169)” | “NA” | “NA” |

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)

<a id="topic-2.2.2.1.3-7"></a>

###### OAKS and DERBY: primary endpoint at month 12 and visual function endpoints

> “The primary endpoint was the change from baseline to month 12 in the total area of geographic atrophy lesions in the study eye based on fundus autofluorescence imaging”
> “In DERBY, pegcetacoplan monthly and pegcetacoplan every other month slowed geographic atrophy lesion growth, although it did not reach significance, by 12%”
> “There were no differences in key secondary visual function endpoints at 24 months.”

Source: [Heier et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37865470/)

<a id="topic-2.2.2.1.3-8"></a>

###### OAKS and DERBY: guideline summary of lesion growth reductions

> “In OAKS, the primary endpoint at 12 months was met with monthly pegcetacoplan reducing GA growth by 21% compared with sham and EOM pegcetacoplan reducing GA growth by 16%.”
> “At 24 months, monthly pegcetacoplan and EOM pegcetacoplan reduced the GA growth rate by 22% and 18% compared with sham, respectively.”
> “Subgroup analysis of the eyes with non-foveal-involving GA showed reduced growth rates by 26% in the monthly arm and 23% in the EOM arm compared with sham.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.2.1.3-9"></a>

###### GALE open-label extension: up to 36 months of pegcetacoplan

> “Through the first 12 months of GALE, 92.0% (727/790) patient retention was observed.”
> “Across all eyes, including eyes with nonsubfoveal and subfoveal GA, pegcetacoplan reduced the mean rate of change in GA area up to 32% versus projected sham.”
> “Adverse events included 33 (4.5%) eyes with exudative AMD, 15 (1.9%) intraocular inflammation (classified as mild or moderate in severity), 1 (0.1%) ischemic optic neuropathy, and 1 (0.1%) infectious endophthalmitis.”
> “No events of vasculitis were reported.”

Source: [Wykoff et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40280279/)

<a id="topic-2.2.2.1.3-10"></a>

###### GALE open-label extension: up to 48 months, early versus delayed treatment

> “The delayed treatment group included sham-observed eyes from OAKS and DERBY which crossed over at 24 months to receive pegcetacoplan treatment for 24 months in the GALE OLE.”
> “In the overall population, 48 continuous months of pegcetacoplan treatment reduced GA area growth rate by up to 24% compared with projected sham, translating to 1.88 mm2 of retinal tissue.”
> “GALE safety data were consistent with the findings of the OAKS and DERBY studies.”

Source: [Dhoot et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665201/)

<a id="topic-2.2.2.1.3-11"></a>

###### Pegcetacoplan: postmarketing retinal vasculitis case series

> “Fourteen eyes of 13 patients were confirmed to have retinal vasculitis by review of imaging studies.”
> “All cases occurred after the first pegcetacoplan injection.”
> “Occlusive retinal vasculopathy was confirmed in 11 eyes (79%).”
> “Eight eyes (57%) had more than a 3-line decrease in VA, and 6 eyes (43%) had more than a 6-line decrease in VA from baseline to the final follow-up, including 2 eyes that were enucleated.”

Source: [Witkin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10786078/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Complement C5 Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### Avacincaptad pegol: mechanism

> “Avacincaptad pegol (ACP) is a pegylated RNA aptamer that inhibits complement C5.”

Source: [Khanani et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41407269/)

<a id="topic-2.2.2.1.4-2"></a>

###### Avacincaptad pegol: indication, dosage, and contraindications

> “Initial U.S. Approval: 2023”
> “IZERVAY® is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).”
> “The recommended dosage for IZERVAY is 2 mg (0.1 mL of 20 mg/mL solution) administered by intravitreal injection to each affected eye once monthly (approximately every 28 ± 7 days).”
> “IZERVAY is contraindicated in patients with active intraocular inflammation.”

Source: [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf)

<a id="topic-2.2.2.1.4-3"></a>

###### Avacincaptad pegol: neovascular AMD and intraocular pressure warnings

> “In the GATHER1 and GATHER2 clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12.”
> “Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group.”
> “Patients receiving IZERVAY should be monitored for signs of neovascular AMD.”
> “Transient increases in intraocular pressure (IOP) have been observed after an intravitreal injection, including with IZERVAY”
> “The most common adverse reactions (incidence ≥ 5%) were conjunctival hemorrhage, increased IOP, blurred vision, neovascular age-related macular degeneration, punctate keratitis, and eye pain”

Source: [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf)

<a id="topic-2.2.2.1.4-4"></a>

###### GATHER1 and GATHER2: design

> “The safety and efficacy of IZERVAY were demonstrated in two randomized, multi-center, double-masked, sham-controlled, 18- and 24-month studies (GATHER1-NCT02686658 and GATHER2-NCT04435366, respectively) in patients with GA due to AMD.”
> “Patients receiving monthly IZERVAY were re-randomized at Month 12 to receive either IZERVAY monthly (EM) or every other month (EOM).”
> “At any time during the GATHER2 study, patients that developed choroidal neovascularization were concomitantly treated with anti-VEGF therapy.”

Source: [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf)

<a id="topic-2.2.2.1.4-5"></a>

###### GATHER1 and GATHER2: GA growth with monthly dosing

| Study and time point | Avacincaptad pegol, N | Sham, N | GA rate of growth, avacincaptad pegol (mm2/year) | GA rate of growth, sham (mm2/year) | Difference (95% CI) (mm2/year) | Difference % | p value |
| --- | --- | --- | --- | --- | --- | --- | --- |
| GATHER1, month 12 | “N=67” | “N=110” | “1.22” | “1.89” | “0.67 (0.21-1.13)” | “35%” | “<0.01” |
| GATHER2, month 12 | “N=225” | “N=222” | “1.75” | “2.12” | “0.38 (0.12-0.63)” | “18%” | “<0.01” |
| GATHER2, month 24 (monthly in both years) | “N=96” | “N=203” | “2.23” | “2.59” | “0.36 (0.07 – 0.66)” | “14%” | “0.0165” |

Source: [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf)

> “Over a 12-month period, there was a statistically significant reduction of the rate of GA growth (0.05 mm/year; p<0.01 with square root transformed data) in patients treated with IZERVAY EM compared to sham.”
> “In the treatment arm that included patients who received IZERVAY EM treatment for one year and EOM treatment for the second year, the annualized rate of GA growth was 2.10 mm2/year.”

Source: [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf)

<a id="topic-2.2.2.1.4-6"></a>

###### GATHER1: phase 2/3 primary endpoint

> “A total of 286 participants with GA secondary to AMD.”
> “The reduction in the mean rate of GA growth (square root transformation) over 12 months was 27.4% (P = 0.0072) for the avacincaptad pegol 2 mg cohort and 27.8% (P = 0.0051) for the avacincaptad pegol 4 mg cohort compared with their corresponding sham cohorts.”

Source: [Jaffe et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32882310/)

<a id="topic-2.2.2.1.4-7"></a>

###### GATHER2: 12-month primary endpoint and safety

> “To be eligible, patients had to be aged 50 years or older with non-centrepoint-involving geographic atrophy and best corrected visual acuity between 20/25 and 20/320 in the study eye.”
> “Between June 22, 2020, and July 23, 2021, 1422 patients were screened for eligibility, of whom 448 were enrolled and randomly assigned to avacincaptad pegol 2 mg (n=225) or sham (n=223).”
> “representing a 14% difference between the avacincaptad pegol 2 mg group and the sham group”
> “There were no endophthalmitis, intraocular inflammation, or ischaemic optic neuropathy events over 12 months.”
> “To month 12, macular neovascularisation in the study eye occurred in 15 (7%) patients in the avacincaptad pegol 2 mg group and nine (4%) in the sham group, with exudative macular neovascularisation occurring in 11 (5%) in the avacincaptad pegol 2 mg group and seven (3%) in the sham group.”

Source: [Khanani et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37696275/)

<a id="topic-2.2.2.1.4-8"></a>

###### GATHER2: two-year results

> “Overall, 175 and 184 patients in the ACP and sham group completed the study at year 2, respectively.”
> “From baseline to year 2, the mean rate of GA area growth was 4.46 mm2 (standard error [SE], 0.25 mm2) with ACP EM and 5.18 mm2 (SE, 0.17 mm2) with sham, a difference in growth of 0.724 mm2 (95% confidence interval [CI], 0.133-1.315 mm2; P = 0.0165), representing a 14% difference.”
> “The incidence of choroidal neovascularization (study eye) was 11.6% with ACP (all treated) versus 9.0% with sham over 2 years.”
> “No events of retinal vasculitis, ischemic optic neuropathy, or serious intraocular inflammation occurred over 2 years.”

Source: [Khanani et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41407269/)

<a id="topic-2.2.2.1.4-9"></a>

###### GATHER2: guideline summary of lesion growth reductions

> “GATHER2 was a phase 3 clinical trial with 448 study participants with foveal-sparing GA.”
> “At 12 months, square-root-transformed GA area growth rate was reduced by 14% in treated eyes versus sham.”
> “For patients treated monthly in the first 12 months, followed by EOM for months 13 to 24, there was a 19% reduction in mean GA growth rate at month 24.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.2.1.4-10"></a>

###### GATHER1 and GATHER2: post hoc analysis of vision loss

> “A post hoc analysis of 12-month data for pooled ACP 2 mg and sham groups is reported.”
> “Lower proportions of study eyes experienced ≥10-, ≥15-, or ≥20-BCVA letter loss from baseline over 12 months with ACP 2 mg (11.6%, 4.0%, and 1.6%, respectively) versus sham (14.1%, 7.6%, and 4.5%, respectively).”
> “There was a reduction in the risk of persistent loss of ≥15 BCVA ETDRS letters with ACP 2 mg (3.4%) versus sham (7.8%) through 12 months.”

Source: [Danzig et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38719191/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Vision Rehabilitation

<a id="topic-2.2.2.1.5-1"></a>

###### Referral for vision rehabilitation in AMD

> “An important component of care for a patient with AMD is referral for vision rehabilitation as well as continued follow-up for general eye care.”
> “Vision rehabilitation optimizes the patient’s functional ability”
> “patients with reduced visual function should be referred for vision rehabilitation and social services”
> “Patients with severe visual loss related to AMD who are referred for vision rehabilitation services often have unrealistic expectations.”
> “Special optical or electronic magnifying lenses, bright lights, and electronic reading aids may help patients to read more effectively but not as well as they did before the onset of AMD.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.2.1.5-2"></a>

###### Vision rehabilitation guideline: scope and referral criteria

> “Vision rehabilitation is not reserved for patients with advanced vision loss or severe loss of visual acuity.”
> “Even early or moderate vision loss may result in disability, which can affect visual performance, cause anxiety, interfere with safety and everyday activities, and diminish quality of life.”
> “Less than 20/40 corrected distance visual acuity in the better eye”
> “Advise patients that vision rehabilitation is an option”

Source: [Jackson et al. (2023)](https://aao.org/Assets/354efadd-457b-4f59-a2ac-66beb0253b72/638070751054170000/vision-rehabilitation-ppp-pdf)

<a id="topic-2.2.2.1.5-3"></a>

###### Vision rehabilitation guideline: reading with central scotoma and eccentric viewing training

> “Even with magnification, reading with nonfoveal retinal fixation does not restore normal continuous print reading speed.”
> “One clinical example of this is patients with macular degeneration who have a scotoma pattern that encircles the fovea, leaving a limited horizontal span for reading or using magnification (foveal-sparing scotoma pattern).”
> “Eccentric viewing training did not significantly improve reading, fixation or task ability measured with the Activity Inventory questionnaire (personal communication).”
> “Even when magnifiers do not restore reading speed to normal fluency for continuous print, magnifiers or cell phone cameras will assist with spot reading tasks such as reading a price tag or a medication label.”

Source: [Jackson et al. (2023)](https://aao.org/Assets/354efadd-457b-4f59-a2ac-66beb0253b72/638070751054170000/vision-rehabilitation-ppp-pdf)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Limitations of Current Therapies

<a id="topic-2.2.2.1.6-1"></a>

###### Summary: limitations of complement inhibitor therapy

Two intravitreal complement inhibitors are approved by the FDA for geographic atrophy: pegcetacoplan (C3 inhibitor), given every 25 to 60 days, and avacincaptad pegol (C5 inhibitor), given once monthly (approximately every 28 ± 7 days). Both reduced the growth of geographic atrophy lesions in sham-controlled phase 3 trials (pegcetacoplan by 22% monthly and 18% every other month at 24 months in OAKS; avacincaptad pegol by 14% in square-root-transformed growth at 12 months and by 14% at 24 months with monthly dosing in GATHER2). Neither improved visual function: the AAO Preferred Practice Pattern states that “There was no benefit for BCVA in the clinical trials for either pegcetacoplan or avacincaptad pegol”, and the 2023 Cochrane review of 10 randomized trials (4052 participants) found “no evidence that complement inhibition with any agent improves functional endpoints in advanced AMD”. The avacincaptad pegol finding of fewer eyes with persistent vision loss comes from a post hoc analysis of 12-month data.

Treatment requires indefinite intravitreal injections. In OAKS and DERBY, 21% to 31% of participants in the pegcetacoplan arms discontinued treatment before month 24. In a retrospective real-world cohort of eyes treated with pegcetacoplan or avacincaptad pegol, retention declined over the first 12 months, and pegcetacoplan treatment (hazard ratio 3.32), new neovascular AMD (odds ratio 3.02), and poor baseline visual acuity were associated with attrition.

Both products increase conversion to neovascular AMD: 12% with monthly and 7% with every-other-month pegcetacoplan against 3% with control by month 24, and 12% with avacincaptad pegol against 9% with sham over 24 months in GATHER2. Pegcetacoplan carries a warning for retinal vasculitis and/or retinal vascular occlusion, which may occur with the first dose and may cause severe vision loss. A postmarketing case series confirmed retinal vasculitis in 14 eyes of 13 patients, all after the first injection, with a more than 6-line loss of visual acuity in 6 eyes (43%); the guideline cites a postmarketing rate of 0.01% per injection. No retinal vasculitis was reported in the pivotal trials, which had no protocol for angiography in eyes with intraocular inflammation.

Neither product is authorized in the European Union. The European Medicines Agency confirmed its recommendation to refuse marketing authorisation for pegcetacoplan on 19 September 2024 because slowing lesion growth “did not lead to clinically meaningful benefits for patients”, and Astellas withdrew its application for avacincaptad pegol on 24 October 2024 after the Agency's provisional opinion that the product could not have been authorised. NICE suspended its appraisal of pegcetacoplan in February 2025, after the company reported that it did not receive marketing authorisation from the MHRA and has since discontinued it. The guideline notes that long-term, real-world data for both products are lacking.

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf); [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf); [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf); [Heier et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37865470/); [Khanani et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37696275/); [Khanani et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41407269/); [Danzig et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38719191/); [Tzoumas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10266126/); [Bhavsar et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42534291/); [Witkin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10786078/); [European Medicines Agency Syfovre (2025)](https://www.ema.europa.eu/en/medicines/human/EPAR/syfovre); [European Medicines Agency Izelvay (2025)](https://www.ema.europa.eu/en/medicines/human/EPAR/izelvay); [National Institute for Health and Care Excellence pegcetacoplan appraisal (2026)](https://www.nice.org.uk/guidance/discontinued/gid-ta11351)

<a id="topic-2.2.2.1.6-2"></a>

###### No visual function benefit in the pivotal trials

> “In both trials, there was no difference in either treatment arm versus sham for functional testing, including best corrected VA (BCVA), mesopic microperimetry, and reading speed.”
> “There was no difference in treatment group versus sham for functional tests of BCVA and low luminance BCVA.”
> “There was no benefit for BCVA in the clinical trials for either pegcetacoplan or avacincaptad pegol, although the post hoc analysis for avacincaptad pegol suggested a possible slowing of progression to persistent vision loss.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.2.1.6-3"></a>

###### Guideline position on monitoring, long-term data, and shared decision-making

> “Because of the risk of exudative AMD, patients should be monitored and treated if needed.”
> “Pegcetacoplan and avacincaptad pegol are both relatively new medications for which long-term, real-world data are lacking.”
> “The physician should discuss the use of these medications with the patient, based on individual circumstances, including documented treatment benefits and risks.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.2.1.6-4"></a>

###### Pooled effects of complement inhibitors on visual acuity, lesion growth, and adverse events

> “Ten RCTs with 4052 participants and eyes with GA were included.”
> “For 242 participants in one study, pegcetacoplan probably did not meaningfully change BCVA given monthly (+1.05 letters, 95% CI −2.71 to 4.81) or EOM (−1.42 letters, 95% CI −5.25 to 2.41), as supported by moderate‐certainty evidence.”
> “These reductions correspond to 19.2% and 14.8% versus sham, respectively.”
> “In a study of 260 participants with extrafoveal or juxtafoveal GA, monthly avacincaptad pegol probably did not result in a clinically meaningful change in BCVA at 2 mg (+1.39 letters, 95% CI −5.89 to 8.67) or 4 mg (−0.28 letters, 95% CI −8.74 to 8.18), based on moderate‐certainty evidence.”
> “However, there is currently no evidence that complement inhibition with any agent improves functional endpoints in advanced AMD; further results from the phase 3 studies of pegcetacoplan and avacincaptad pegol are eagerly awaited.”
> “Progression to MNV or exudative AMD is a possible emergent adverse event of complement inhibition, requiring careful consideration should these agents be used clinically.”
> “Intravitreal administration of complement inhibitors is probably associated with a small risk of endophthalmitis, which may be higher than that of other intravitreal therapies.”

Source: [Tzoumas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10266126/)

<a id="topic-2.2.2.1.6-5"></a>

###### Patient acceptability of injections conditional on functional benefit

> “Intravitreal complement inhibitors injections (IVCIs) slowed progression of geographic atrophy (GA) lesions in several registration phase 3 trials although without benefit for prespecified secondary functional vision outcomes.”
> “This cross-sectional study of 153 UK-based patients with GA, more than half found intravitreal injections for GA at least very acceptable, assuming treatment had vision functional benefits.”

Source: [Dinah et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12464851/)

<a id="topic-2.2.2.1.6-6"></a>

###### Treatment discontinuation in OAKS and DERBY

> “In OAKS, 31% of patients in the monthly group, 21% of patients in the every other month and 25% of the patients assigned to sham discontinued treatment prior to Month 24.”
> “In DERBY, 29% of patients in the monthly group, 22% of patients in the every other month and 21% of the patients assigned to sham discontinued treatment prior to Month 24.”

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)

<a id="topic-2.2.2.1.6-7"></a>

###### Real-world attrition on complement inhibitor therapy

> “To identify characteristics of patients with geographic atrophy (GA) who received pegcetacoplan or avacincaptad pegol and discontinued treatment.”
> “Treatment retention declined between 0 and 12 months.”
> “Baseline predictors of attrition were age older than 90 years (HR, 1.26; 95% CI, 1.03-1.55; P = .028), pegcetacoplan treatment (HR, 3.32; 95% CI, 2.92-3.76; P < .001)”
> “Significant predictors included new nAMD (OR, 3.02; 95% CI, 2.35-3.89; P < .001) and a loss of more than 5 ETDRS letters (OR, 1.36; 95% CI, 1.17-1.58; P < .001).”
> “Poor baseline vision and development of new nAMD are associated with patient attrition, and the combination of nAMD and GA and treatment burden challenges patient retention.”

Source: [Bhavsar et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42534291/)

<a id="topic-2.2.2.1.6-8"></a>

###### New-onset exudative AMD with pegcetacoplan in OAKS and DERBY

> “New-onset exudative age-related macular degeneration was reported in 24 (11%), 16 (8%), and four (2%) patients in OAKS, and in 27 (13%), 12 (6%), and nine (4%) patients in DERBY receiving pegcetacoplan monthly, pegcetacoplan every other month, and sham, respectively, at 24 months.”

Source: [Heier et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37865470/)

<a id="topic-2.2.2.1.6-9"></a>

###### Retinal vasculitis and intraocular inflammation after pegcetacoplan

> “Postmarketing surveillance revealed retinal vasculitis occurred at a rate of 0.01% per injection and appears to occur more commonly following the first injection at a rate of 1/4000 first injections.”
> “Pegcetacoplan was found to have a 2.1% to 3.8% rate of intraocular inflammation (not counting endophthalmitis).”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

> “There were no reported cases of retinal vasculitis or occlusive retinal vasculopathy in the clinical trials.”
> “Notably, however, there was no defined protocol in these studies to obtain angiography in cases of intraocular inflammation.”
> “Voluntary reporting of adverse events is inherently subject to underreporting, and it is possible that some cases of retinal vasculitis have not been reported to the ReST Committee, the company, or the FDA.”

Source: [Witkin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10786078/)

<a id="topic-2.2.2.1.6-10"></a>

###### European Medicines Agency refusal of pegcetacoplan

> “After re-examining its initial opinion, the European Medicines Agency issued its final opinion on 19 September 2024 in which it confirmed its recommendation to refuse marketing authorisation for Syfovre.”
> “At the time of the initial evaluation, although the studies showed that Syfovre slowed the growth of geographic atrophy lesions, the Agency considered that this did not lead to clinically meaningful benefits for patients.”
> “It was noted that benefits of a treatment should have an impact on patients’ everyday functioning, and this was not demonstrated in the studies.”
> “In terms of safety, regular injections into the eye carry a significant risk of adverse events, including the development of other forms of AMD or inflammation in the eye, which could further worsen vision.”

Source: [European Medicines Agency Syfovre (2025)](https://www.ema.europa.eu/en/medicines/human/EPAR/syfovre)

<a id="topic-2.2.2.1.6-11"></a>

###### Withdrawal of the European marketing authorisation application for avacincaptad pegol

> “Astellas Pharma Europe B.V. withdrew its application for a marketing authorisation of Izelvay, a medicine intended for the treatment of geographic atrophy caused by age-related macular degeneration (AMD).”
> “The company withdrew the application on 24 October 2024.”
> “Although the studies provided by the applicant showed that Izelvay slowed the growth of geographic atrophy lesions, the Agency considered that this effect did not lead to clinically meaningful improvements in visual function for patients.”
> “In its letter notifying the Agency of the withdrawal of the application, the company stated that it withdrew the application because of the Agency’s concerns about the effectiveness of the medicine.”

Source: [European Medicines Agency Izelvay (2025)](https://www.ema.europa.eu/en/medicines/human/EPAR/izelvay)

<a id="topic-2.2.2.1.6-12"></a>

###### Discontinued NICE appraisal of pegcetacoplan

> “For information, the company have advised that they did not receive Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication.”
> “Please note that following on from information provided to NICE by the company in February 2025, the appraisal was suspended from NICE’s work programme.”
> “As no further information has been received from the company the topic has been discontinued.”

Source: [National Institute for Health and Care Excellence pegcetacoplan appraisal (2026)](https://www.nice.org.uk/guidance/discontinued/gid-ta11351)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: anticipated use and care setting

Vonaprument is not approved for any use. In the phase 3 ARCHER II trial it is given as 5.0 mg per eye by monthly intravitreal injection, which places its anticipated use among physician-administered intravitreal therapies, the same route and setting as the two approved complement inhibitors for geographic atrophy, pegcetacoplan and avacincaptad pegol. The AAO Preferred Practice Pattern states that the ophthalmologist should administer all treatment and anti-VEGF injections for AMD. A U.S. expert panel recommends nonurgent referral to a retina specialist for any suspected geographic atrophy and notes that current anti-complement therapy requires “office visits every 1 to 2 months”.

In a footnote that begins “Based on market reports”, the sponsor estimates that approximately 75,000 U.S. patients are actively treated with available therapies, about 10% of the 800,000 people diagnosed with geographic atrophy or under the care of retina specialists and about 5% of an estimated 1.5 million U.S. people with geographic atrophy. Medicare Part B fee-for-service data for 2025 record 32,021 beneficiaries with 168,366 claims for pegcetacoplan and 27,497 beneficiaries with 140,741 claims for avacincaptad pegol, with total spending of about $451.1 million and $364.9 million. For the first quarter of 2026 the counts were 24,179 and 23,315 beneficiaries. No source states a planned price, distribution model, or position in a treatment sequence for vonaprument.

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b); [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy); [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf); [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/); [CMS Medicare Quarterly Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/bf6a5b3b-31ee-4abb-b1ad-2607a1e7510a/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2781&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2782)

<a id="topic-2.2.2.2-2"></a>

###### Investigational dose, frequency, and route

> “Vonaprument (ANX007) Monthly 5.0 mg/eye”
> “25 microliter dose”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

> “It is formulated for intravitreal (IVT) administration, with the potential to be the first targeted vision-preserving therapy for GA.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-2.2.2.2-3"></a>

###### Provider and setting for intravitreal treatment of AMD

> “The ophthalmologist should perform the examination, order appropriate testing, and administer all treatment and anti-VEGF injections”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.2.2-4"></a>

###### Referral to retina specialists and office visit frequency for approved complement inhibitors

> “A nonurgent referral to a retina specialist is recommended for any suspected GA in one or both eyes, whereas a more urgent referral should be made for any patient with suspected neovascular AMD (nAMD)”
> “To streamline care, patients may consider monitoring (or possibly even treatment) by their comprehensive ophthalmologist under the guidance of a retina specialist, which may help maintain compliance and overall treatment fidelity.”
> “Current anti-complement therapy for GA requires treatment with office visits every 1 to 2 months.”
> “Timing of referral to retina specialists must be optimized to consider the burden on patients and caregivers.”

Source: [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)

<a id="topic-2.2.2.2-5"></a>

###### Sponsor estimate of the treated and untreated U.S. population

> “Based on market reports, approximately 75,000 patients are being actively treated with available therapies in the US, representing ~10% of the 800,000 people diagnosed with GA/under the care of retina specialists, but only about 5% of the 1.5M US population with GA”
> “of US patients being treated today”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-2.2.2.2-6"></a>

###### Medicare Part B use of approved complement inhibitors for geographic atrophy

| Brand name | HCPCS description | Period | Beneficiaries | Claims | Total spending (USD) |
| --- | --- | --- | --- | --- | --- |
| “SYFOVRE” | “INJ, PEGCETACOPLAN, 1MG” | “2025 (Q1-Q4)” | “32021” | “168366” | “451069360.05” |
| “SYFOVRE” | “INJ, PEGCETACOPLAN, 1MG” | “2026 (Q1)” | “24179” | “41654” | “109568082.68” |
| “IZERVAY” | “INJ AVACINCAPTAD PEGOL 0.1MG” | “2025 (Q1-Q4)” | “27497” | “140741” | “364934587.1” |
| “IZERVAY” | “INJ AVACINCAPTAD PEGOL 0.1MG” | “2026 (Q1)” | “23315” | “41264” | “105232261.84” |

Source: [CMS Medicare Quarterly Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/bf6a5b3b-31ee-4abb-b1ad-2607a1e7510a/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2781&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2782)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Lesion location: foveal and non-foveal subgroups, stratified combined analysis (topline data)

> “The study enrolled a total of 270 patients, stratified by GA lesion size, location and choroidal neovascularization (CNV) in the fellow eye at the time of enrollment.”
> “When assessing the BCVA treatment effect by lesion location, the combined analysis, stratified by foveal and non-foveal patients, demonstrated an overall statistically significant difference between ANX007 and sham:”
> “In this study, loss was defined as loss of 15 BCVA letters or more on two consecutive visits, or a loss at the end of the 12-month treatment period.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

| Lesion location | Sham | Vonaprument every month | Vonaprument every other month | Vonaprument pooled |
| --- | --- | --- | --- | --- |
| Foveal | “25.0%” “(11/44)” | “5.9%” “(3/51)” | “18.4%” “(9/49)” | “12.0%” “(12/100)” |
| Non-foveal | “17.8%” “(8/45)” | “5.3%” “(2/38)” | “2.3%” “(1/43)” | “3.7%” “(3/81)” |
| Stratified p value versus sham | “--” | “0.0019” | “0.0439” | “0.0015” |

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-2.2.2.3-2"></a>

###### Lesion location: final data with nominal p values within each subgroup

> “Eyes treated with vonaprument lost meaningfully less vision through 12 months compared to sham in 15-letter loss assessments of BCVA irrespective of lesion location”
> “Treatment effect, dose response, and statistical results were generally consistent with outcomes for the overall population in ARCHER”
> “Nominal p-value from a Chi-square test population in relevant lesion location subpopulation; Final data”
> “Nominal p-value from a Cochran-Mantel-Haenszel test (General Association) in overall population; Final data”

Source: [Goren Fein et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/J-Goren-Fein-RWC-Poster-FINAL-11May26.pdf)

| Lesion location | Sham | Vonaprument every other month | Vonaprument every month |
| --- | --- | --- | --- |
| Foveal, participants with loss | “25.0%” “11/44” | “16.3%” “8/49” | “5.9%” “3/51” |
| Foveal, nominal p value versus sham | “---” | “.3003” | “.0088” |
| Non-foveal, participants with loss | “17.8%” “8/45” | “2.3%” “1/43” | “5.3%” “2/38” |
| Non-foveal, nominal p value versus sham | “---” | “.0168” | “.0810” |

Source: [Goren Fein et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/J-Goren-Fein-RWC-Poster-FINAL-11May26.pdf)

<a id="topic-2.2.2.3-3"></a>

###### Subfoveal retinal pigment epithelium lesions: post hoc analysis

> “Vision Outcomes in Eyes with Subfoveal RPE Lesions in Geographic Atrophy: A Post Hoc Analysis of the Phase 2 ARCHER Trial”
> “Historically, GA with subfoveal involved lesions was considered too advanced to show a meaningful treatment benefit”
> “76% Risk Reduction Vonaprument EM”
> “HR (CI) = 0.242 (0.067 to 0.881); Nominal p = .0204*”
> “41% Risk Reduction Vonaprument EOM”
> “HR (CI) = 0.504 (0.225 to 1.555); Nominal p = .2784”
> “Vision protection in the subfoveal population was shown across several key visual acuity measures, including:”

Source: [Barakat (2026)](https://annexonbio.com/wp-content/uploads/2026/09/913_Friday_Barakat_-Vision-Outcomes-in-Eyes-With-Subfoveal-RPE-Lesions-in-Geographic-Atrophy-A-Post-Hoc-Analysis-of-the-Phase-2-ARCHER-Trial-FINAL-25Sept26.pdf)

<a id="topic-2.2.2.3-4"></a>

###### Baseline low-luminance visual deficit: healthier and less healthy retina, stratified combined analysis (topline data)

> “When assessing the BCVA treatment effect by retinal health, the combined analysis, stratified by healthier and less healthy retina, demonstrated an overall statistically significant difference between ANX007 and sham.”
> “This effect supports the potential use as an early treatment for GA:”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

| Baseline LLVD | Sham | Vonaprument every month | Vonaprument every other month | Vonaprument pooled |
| --- | --- | --- | --- | --- |
| Below 30 (healthier) | “16.9%” “(10/59)” | “0.0%” “(0/56)” | “6.3%” “(3/48)” | “2.9%” “(3/104)” |
| 30 or higher (less healthy) | “30.8%” “(8/26)” | “16.1%” “(5/31)” | “16.3%” “(7/43)” | “16.2%” “(12/74)” |
| Stratified p value versus sham | “--” | “0.0016” | “0.029” | “0.0009” |

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-2.2.2.3-5"></a>

###### Less advanced disease: low-luminance deficit, lesion size, and ellipsoid zone integrity (additional analyses)

> “Additional analyses were conducted to evaluate the effect of ANX007 on these measures in participants with relatively less advanced disease at baseline (less EZ loss and lower low luminance visual deficit [LLVD]).”

Source: [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf)

> “Lower low luminance visual deficit = more robust ANX007 response”
> “Smaller lesions = more robust ANX007 response”
> “More EZ remaining = more pronounced ANX007 response”
> “ANX007 has even greater effect in eyes with less advanced disease – lower LLVD, smaller GA lesions, more intact EZ”

Source: [Stanga et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/12/Stanga-FloRetina-Final-Dec24.pdf)

<a id="topic-2.2.2.3-6"></a>

###### Baseline characteristics associated with confirmed loss of 15 or more letters

> “BCVA ≥15-letter loss did not occur in participants with baseline BCVA <44 letters”
> “BCVA ≥15-letter loss less frequent in participants with baseline BCVA >69 letters”
> “Confirmed loss of 15 or more BCVA letters was associated with:”
> “Baseline visual acuity (BCVA) above 45 letters (20/100)”
> “All lesion types – more strongly associated in those with subfoveal lesions”

Source: [Chang (2026)](https://annexonbio.com/wp-content/uploads/2026/07/MChang-ASRS-Presentation-FINAL-18Jul26.pptx.pdf)

> “Individuals with baseline BCVA <45 letters not enrolled in ARCHER II due to very low incidence of BCVA 15-letter loss in ARCHER”
> “Enrolled patients at risk for vision loss but with enough vision to protect”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Monitoring for conversion to neovascular AMD during complement inhibitor therapy

> “Because of the risk of exudative AMD, patients should be monitored and treated if needed.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

> “If an eye develops nAMD during GA treatment, nAMD treatment will need to be initiated if there are signs of exudation in the macula.”
> “Combined GA and nAMD treatment is both feasible and safe based on pivotal clinical trials, but injections may need to be provided either on different clinical visits or separated by approximately 30 min if performed on the same day to minimize the risk of excessive intraocular pressure elevation.”

Source: [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)

<a id="topic-2.2.2.4-2"></a>

###### Self-monitoring and electronic home monitoring

> “Patients with a high-risk AMD phenotype are at increased risk of progression to advanced AMD and should be educated about methods of detecting new symptoms of MNV, including self-monitoring.”
> “Electronic monitoring devices are now available to aid in the detection of neovascularization at an early stage.”
> “Since some patients with AMD also have cognitive impairment, a family member or care assistant should prompt the patient to self-test.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

> “Additionally, it is suggested that the patient consider self-monitoring between visits using Amsler grid testing or with the use of preferential hyperacuity perimetry home testing.”

Source: [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)

<a id="topic-2.2.2.4-3"></a>

###### Follow-up visits: history and examination

> “A history and examination are the recommended elements of the follow-up visits, and the recommended follow-up intervals are listed in Table 6.”
> “Changes in medications and nutritional supplements”
> “Visual acuity at distance with correction”
> “Stereoscopic biomicroscopic examination of the fundus”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

> “As with many diseases, the severity and rate of progression will vary from patient to patient. Therefore, adjustments to follow-up frequency should be considered depending on the identification of signs of increased risk, such as advanced age, family history, smoking history, and whether the patient is monocular.”

Source: [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)

<a id="topic-2.2.2.4-4"></a>

###### Patient education and shared decision-making

> “The physician should discuss the use of these medications with the patient, based on individual circumstances, including documented treatment benefits and risks.”
> “All patients with AMD should be educated about the prognosis of the disease and the potential value of treatment as appropriate for their visual and functional status.”
> “Patients can be informed that while central visual loss is common, total visual loss is extremely rare.”
> “Insofar as cigarette smoking is a key modifiable risk factor, smoking cessation is strongly recommended when advising patients with AMD or at risk for AMD.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

> “Additionally, the physician should educate the patient with regard to GA progression and treatment expectations.”
> “Additionally, the treating physician should educate patients on symptoms that may signify occurrence of adverse events, such as pain, new visual changes, or new floaters.”

Source: [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)

<a id="topic-2.2.2.4-5"></a>

###### Treatment selection and discontinuation for approved complement inhibitors

> “In general, treatment decisions are influenced by patient symptoms, visual acuity, age, fellow-eye status, and ocular comorbidities, as well as the discretion of the physician and patient to conduct a comprehensive personalized risk-benefit assessment that is guided by a general evidence-based treatment algorithm.”
> “Several circumstances may warrant discontinuation of GA treatment, such as the occurrence of severe adverse events including endophthalmitis, ischemic optic neuropathy, sustained elevation of intraocular pressure, and significant, nontransient intraocular inflammation, especially if associated with any retinal vasculitis or occlusive vasculitis.”
> “Additionally, severe central vision loss may represent a scenario where ongoing treatment risks or burdens may not significantly outweigh any potential benefits.”

Source: [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Sponsor statements of the intended outcome

> “It is formulated for intravitreal (IVT) administration, with the potential to be the first targeted vision-preserving therapy for GA.”
> “Vonaprument involves a differentiated neuroprotective approach designed to protect photoreceptor cells and retinal function by blocking C1q and the entire classical pathway, while allowing for normal immune activity of the lectin and alternative complement pathways.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

> “Assuming success in the ARCHER II trial, ANX007 has the potential to be the first GA therapy approved to protect vision.”

Source: [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)

> “Vision protection is what matters to patients, physicians and payers.”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-2.2.2.7-2"></a>

###### Expected outcome of ARCHER II and its uncertainty

> “ARCHER II is designed to demonstrate clinically meaningful vision protection at Months 15 and 24. Given the linear progression of vision loss in GA, we believe longer treatment provides greater potential for sustained treatment benefit and increased separation between vonaprument treatment and sham over time.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

> “Under the dual primary endpoint design, ARCHER II may achieve statistical success at either the Month 15 or Month 24 timepoint.”
> “However, there is no assurance that either timepoint will show a statistically significant treatment effect”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-2.2.2.7-3"></a>

###### Phase 2 basis: primary lesion-growth endpoint not met and prespecified visual acuity analyses

> “The primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance.”
> “A 6.2% reduction in lesion growth was observed in monthly treatment group (p=0.526), a 1.3% reduction was observed in the every-other-month treatment group (p-value=0.896) and a 3.7% reduction was observed in the pooled patient population (p-value=0.673).”
> “The study included multiple pre-specified visual function measures to assess the effects of ANX007 on vision:”
> “Over the 12-month treatment period, patients in the ANX007 monthly treatment group showed a 72% reduction in risk of >15-letter vision loss (n=89, p=0.006) and patients in the ANX007 every-other-month treatment group showed a 48% reduction in risk of >15-letter vision loss (n=92, p=0.064).”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-2.2.2.7-4"></a>

###### Number needed to treat to avoid confirmed vision loss (prespecified secondary analysis, nominal p values)

> “A Prespecified Secondary Analysis”
> “Nominal p-value from a Chi-square test in ITT population”
> “For every 7 patients treated with ANX007 monthly, 1 additional patient would be spared clinically significant vision loss”
> “Number Needed to Treat EM To Avoid ≥10 LL = 10”
> “Number Needed to Treat EM To Avoid ≥20 LL = 8”

Source: [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf)

<a id="topic-2.2.2.7-5"></a>

###### Persistence of effect after treatment cessation

> “While benefit was maintained after treatment cessation the rate of BCVA≥15 LL increased to parallel that of sham (>1.6% per month)”
> “Consistent with true on-treatment drug effect and disease-modifying mechanism of action”

Source: [Stanga et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/12/Stanga-FloRetina-Final-Dec24.pdf)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
